var title_f9_61_10192="Hormones renal circulation";
var content_f9_61_10192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanisms of action of the major hormones that affect the renal circulation and tubular function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 167px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10192=[""].join("\n");
var outline_f9_61_10192=null;
var title_f9_61_10193="Reboxetine: International drug information";
var content_f9_61_10193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Reboxetine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Davedax (IT);",
"     </li>",
"     <li>",
"      Edronax (AT, BE, CH, DE, DK, GB, HU, IT, MX, SE);",
"     </li>",
"     <li>",
"      Solvex (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Norepinephrine Reuptake Inhibitor, Selective",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Adults: 4 mg twice daily (8 mg/day). After 3 weeks, the dose can be increased up to 10 mg/day in case of incomplete clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Elderly: 2 mg twice daily (4 mg/day); may increase dose to 6 mg/day after 3 weeks if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     <b>",
"      Dosing adjustment in hepatic/renal impairment:",
"     </b>",
"     2 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 2 mg, 4 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10432 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10193=[""].join("\n");
var outline_f9_61_10193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304024\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980124\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980127\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980121\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821145\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980126\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10432|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_61_10194="Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation";
var content_f9_61_10194=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"GFR_MDRD_Abbrev_form\" name=\"GFR_MDRD_Abbrev_form\" onkeydown=\"formKeyDown(event);\" onkeypress=\"return validNumberField(event);\" onkeyup=\"GFR_MDRD_Abbrev_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          GlomerularFiltrationRate = CreatAssay * SerumCreat",
"          <sup>",
"           -1.154",
"          </sup>",
"          * Age",
"          <sup>",
"           -0.203",
"          </sup>",
"          * Sex * Race",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Creat",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Creat_param\" onblur=\"GFR_MDRD_Abbrev_fx(); minMaxCheck();\" onchange=\"GFR_MDRD_Abbrev_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Creat_unit\" onchange=\"GFR_MDRD_Abbrev_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0113122171945701|0|mcmol/L_Cr\">",
"               mcmol/L",
"              </option>",
"              <option value=\"1|0|mg%_Cr\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Cr\">",
"               mg/dL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Creat Assay",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Creat_Assay_radio\" onclick=\"GFR_MDRD_Abbrev_fx();\" type=\"radio\" value=\"IDMS|175\"/>",
"              IDMS (175)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Creat_Assay_radio\" onclick=\"GFR_MDRD_Abbrev_fx();\" type=\"radio\" value=\"Non-IDMS|186\"/>",
"              Non-IDMS (186)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"GFR_MDRD_Abbrev_fx(); minMaxCheck();\" onchange=\"GFR_MDRD_Abbrev_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"GFR_MDRD_Abbrev_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Sex",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Sex_radio\" onclick=\"GFR_MDRD_Abbrev_fx();\" type=\"radio\" value=\"Female|0.742\"/>",
"              Female (0.742)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Sex_radio\" onclick=\"GFR_MDRD_Abbrev_fx();\" type=\"radio\" value=\"Male|1\"/>",
"              Male (1)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Race",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Race_radio\" onclick=\"GFR_MDRD_Abbrev_fx();\" type=\"radio\" value=\"Black|1.21\"/>",
"              Black (1.21)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Race_radio\" onclick=\"GFR_MDRD_Abbrev_fx();\" type=\"radio\" value=\"Non-Black|1\"/>",
"              Non-Black (1)",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Glomerular Filtration Rate",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Glomerular_Filtration_Rate_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <span style=\"white-space: nowrap;\">",
"               <span class=\"medCalcFontOneBold\">",
"                mL/min/1.73 m",
"                <sup>",
"                 2",
"                </sup>",
"               </span>",
"              </span>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"GFR_MDRD_Abbrev_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       <b>",
"        IDMS",
"       </b>",
"       (Isotope Dilution Mass Spectrometry) indicates a method for determining creatinine concentration that has been standardized using, or traceable to, IDMS. Contact laboratory if uncertain as to whether or not reported values are IDMS-traceable.",
"      </li>",
"      <li>",
"       You can estimate the glomerular filtration rate from the formula if the serum creatinine concentration is stable.",
"      </li>",
"      <li>",
"       The accuracy of the abbreviated MDRD study equation as an estimate of the true glomerular filtration rate is discussed elsewhere in UpToDate.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOne\">",
"     Equation parameters such as",
"     <b>",
"      Creat Assay",
"     </b>",
"     have two or more discrete values that may be used in the calculation. The numbers in the parentheses, eg,  (175), represent the values that will be used.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Levey AS, Greene T, Kusek JW, et. al. A simplified equation to predict glomerular filtration rate from serum creatinine.",
"        <i>",
"         J Am Soc Nephrol",
"        </i>",
"        . 11:A0828, 2000 (abstr).",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10194=[" ",
"",
"",
"var lastChar = '';",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"function alertNaN(){",
"alert('This field is improperly formatted. You may only input the digits 0-9 and a decimal point.');  ",
"doCalc = false; ",
"clrResults();",
"}",
"",
"function validNumberField(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"var val = field.value;",
"var charCode = event.charCode;",
"var key = String.fromCharCode(charCode);",
"",
"if(charCode == 0 || charCode == 13) {",
"  return true;",
"}",
"",
"if(key == ' ') {",
"alert('Numeric field cannot contain spaces.');",
"  return false;",
"}	",
"		",
"if(key == '.') { return validDecimalPoint(val, key); }",
"if(key == '-') { return validMinus(val, key); }",
"",
"if(isNaN(parseInt(key))) {",
"alertNaN();",
"return false;",
"}",
"	",
"return validFloat(val, key);",
"}",
"return true;",
"}",
"",
"function validDecimalPoint(val, key) {",
"if(val.length == 0 && lastChar != '.') {",
"  lastChar = '.';",
"  return true;",
"}",
"if(val.indexOf('.') >= 0 || lastChar == '.') {",
" alertNaN();",
" return false;",
"}",
"if(validFloat(val, key)) {",
" lastChar = key;",
" return true;",
"}",
"lastChar = '';",
"return false;",
"}",
"",
"function validMinus(val, key) {",
"if(val.length == 0) {",
"  return true;",
"}",
"if(val.length > 1) {",
" alertNaN();",
" return false;",
"}",
"return validFloat(val, key);",
"}",
"",
"",
"function validFloat(val, key) {",
"var currentVal = parseFloat(val + key);",
"if(isNaN(val + key) || isNaN(currentVal)) {",
"alertNaN();",
"return false;",
"}",
"return true;",
"}",
"",
"function formKeyDown(event) {",
"var field = event.target;",
"",
"if(field && field != 'undefined' && field.attributes.type.nodeValue && (field.attributes.type.nodeValue == 'number')) {",
"  var val = field.value;",
"  var keyCode = event.keyCode;",
"  if(keyCode == 8 || keyCode == 127) {",
"    // backspace or delete",
"    if(lastChar == '.') {",
"      lastChar = '';",
"    }",
"    if(field.value.length == 3 && field.value[0] == '0' && field.value[1] == '.') {",
"      // this handles a backspace on an input like \".5\", which is saved internally as \"0.5\"",
"      //   otherwise, if you leave the field after the backspace, it retains \"0.5\" as the value, most likely an iOS bug",
"      field.value = ''; ",
"    }",
"  }",
"}",
"clrResults();",
"}",
"",
"function clrValue(field) {",
" field.value = '';",
" lastChar = '';",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function GFR_MDRD_Abbrev_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 2000);",
"",
"with(document.GFR_MDRD_Abbrev_form){",
"",
"",
"doCalc = true;",
"param_value = parseFloat(Serum_Creat_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Creat_unit.options[Serum_Creat_unit.selectedIndex].value.split('|');",
"Serum_Creat = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Creat_Assay_radio[0].checked){ Creat_Assay = 175; }",
"if (Creat_Assay_radio[1].checked){ Creat_Assay = 186; }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Sex_radio[0].checked){ Sex = 0.742; }",
"if (Sex_radio[1].checked){ Sex = 1; }",
"if (Race_radio[0].checked){ Race = 1.21; }",
"if (Race_radio[1].checked){ Race = 1; }",
"dp = decpts.options[decpts.selectedIndex].text;",
"Glomerular_Filtration_Rate =  Creat_Assay * power(Serum_Creat, -1.154) * power(Age, -0.203) * Sex * Race;",
"",
"if (doCalc) Glomerular_Filtration_Rate_param.value = fixDP(Glomerular_Filtration_Rate, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.GFR_MDRD_Abbrev_form){",
"",
"if (Serum_Creat_param.value && isNaN(Serum_Creat_param.value)){ clrValue(Serum_Creat_param); alertNaN(); }",
"if (Age_param.value && isNaN(Age_param.value)){ clrValue(Age_param); alertNaN(); }",
"if (Age_param.value && Age < 0) {",
"Age = 0;",
"clrValue(Age_param);",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 0 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 120) {",
"clrValue(Age_param);",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 120 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.GFR_MDRD_Abbrev_form){",
"",
"Glomerular_Filtration_Rate_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f9_61_10194=null;
var title_f9_61_10195="Patient information: Syphilis (The Basics)";
var content_f9_61_10195=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/4/28738\">",
"         Patient information: Care after rape or sexual assault (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/56/14211\">",
"         Patient information: Choosing birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21906\">",
"         Patient information: Genital herpes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/13/16594\">",
"         Patient information: Genital warts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/35/31282\">",
"         Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1940\">",
"         Patient information: Screening for sexually transmitted diseases (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33570\">",
"         Patient information: Vaginal discharge in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/2/22563\">",
"         Patient information: Barrier methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/30/1509\">",
"         Patient information: Care after sexual assault (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/14/24802\">",
"         Patient information: Chlamydia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/60/4035\">",
"         Patient information: Genital warts in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1730\">",
"         Patient information: Gonorrhea (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/12/27843\">",
"         Patient information: Pubic lice (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40641\">",
"         Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Syphilis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/syphilis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13957722\">",
"      <span class=\"h1\">",
"       What is syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Syphilis is an infection that you can catch during sex. Infections that you can catch during sex are called &ldquo;sexually transmitted infections.&rdquo;",
"     </p>",
"     <p>",
"      Syphilis has different stages. Each stage causes a different set of symptoms. The stages (in the order they happen) are called:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Primary syphilis",
"       </li>",
"       <li>",
"        Secondary syphilis",
"       </li>",
"       <li>",
"        Latent syphilis",
"       </li>",
"       <li>",
"        Late (or tertiary) syphilis",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957737\">",
"      <span class=\"h1\">",
"       What are the symptoms of primary syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Primary syphilis is the first stage of infection. Symptoms start 2 to 3 weeks after the person becomes infected. At that time, the person usually gets a raised red bump on the spot where the infection first entered the body. This bump is usually painless. Eventually it turns into a small sore (or ulcer) with a raised edge.",
"     </p>",
"     <p>",
"      The sores caused by syphilis usually form on the penis or around the vagina or anus. But they can also form in places that are hard to see, such as the back of the throat or inside the vagina or rectum.",
"     </p>",
"     <p>",
"      Sores caused by primary syphilis usually heal on their own within a few weeks. Since they don&rsquo;t hurt, many people don&rsquo;t get treatment for them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957752\">",
"      <span class=\"h1\">",
"       What are the symptoms of secondary syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Secondary syphilis is the second stage of infection. It starts weeks or a few months after primary syphilis and happens in about 25 percent of people who don&rsquo;t get treatment for their primary syphilis.",
"     </p>",
"     <p>",
"      Symptoms of secondary syphilis include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A widespread rash",
"       </li>",
"       <li>",
"        Large, raised, gray or white patches on warm, moist areas of the body (such as the mouth)",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Sore throat, muscle aches, and other flu-like symptoms",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Swollen lymph nodes in the neck, armpit, and groin area (lymph nodes are bean-shaped organs scattered throughout the body that store infection-fighting cells)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957767\">",
"      <span class=\"h1\">",
"       What are the symptoms of latent syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Latent syphilis actually causes no symptoms. People who have this form can have the infection for years without knowing it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957782\">",
"      <span class=\"h1\">",
"       What are the symptoms of late stage syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Late stage syphilis (also called tertiary syphilis) can cause serious damage to the heart, brain, eyes, and other organs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957797\">",
"      <span class=\"h1\">",
"       Is there a test for syphilis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A blood test can show whether you are infected with syphilis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957812\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you should see a doctor or nurse if you have any of the symptoms listed above. You should also see a doctor or nurse if any of your sexual partners have been diagnosed with syphilis. Even if you have no symptoms, you could be infected. If you are infected, there are treatments to cure syphilis.",
"     </p>",
"     <p>",
"      If you see a doctor or nurse to be checked for syphilis, he or she might want to test you for other sexually transmitted infections, too. That&rsquo;s because people who get one type of sexually transmitted infection are often at risk for other types.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957827\">",
"      <span class=\"h1\">",
"       How is syphilis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Syphilis is usually treated with an antibiotic called penicillin. The amount of time a person must take penicillin depends on what stage of infection they are in. People who are allergic to penicillin must take a different antibiotic.",
"     </p>",
"     <p>",
"      After finishing treatment, some people need to be tested for syphilis to make sure they are cured.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957842\">",
"      <span class=\"h1\">",
"       Can syphilis prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting syphilis by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using a latex condom every time you have sex",
"       </li>",
"       <li>",
"        Avoiding sex when you or your partner has any symptoms that could be caused by an infection",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not having sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13957857\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"       Patient information: Screening for sexually transmitted diseases (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       Patient information: Genital warts (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       Patient information: Genital herpes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=see_link\">",
"       Patient information: Vaginal discharge in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"       Patient information: Choosing birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/4/28738?source=see_link\">",
"       Patient information: Care after rape or sexual assault (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=see_link\">",
"       Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       Patient information: Chlamydia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       Patient information: Gonorrhea (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"       Patient information: Genital warts in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       Patient information: Genital herpes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/12/27843?source=see_link\">",
"       Patient information: Pubic lice (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=see_link\">",
"       Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"       Patient information: Barrier methods of birth control (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=see_link\">",
"       Patient information: Care after sexual assault (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/61/10195?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17045 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-25B04CEC5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10195=[""].join("\n");
var outline_f9_61_10195=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957722\">",
"      What is syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957737\">",
"      What are the symptoms of primary syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957752\">",
"      What are the symptoms of secondary syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957767\">",
"      What are the symptoms of latent syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957782\">",
"      What are the symptoms of late stage syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957797\">",
"      Is there a test for syphilis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957812\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957827\">",
"      How is syphilis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957842\">",
"      Can syphilis prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13957857\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=related_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/4/28738?source=related_link\">",
"      Patient information: Care after rape or sexual assault (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=related_link\">",
"      Patient information: Care after sexual assault (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=related_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=related_link\">",
"      Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/12/27843?source=related_link\">",
"      Patient information: Pubic lice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=related_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=related_link\">",
"      Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=related_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_61_10196="Slapped cheek rash";
var content_f9_61_10196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71737%7EID%2F75125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71737%7EID%2F75125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Slapped cheek rash of parvovirus B19",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A child with the characteristic malar (\"slapped cheek\") rash associated with parvovirus B19 (erythema infectiousum, fifth disease).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moise L Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema infectiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticulating pattern of an erythematous eruption on the extremities due to parvorvirus B19. Rash is more common in children. The presence of intense erythema (a slapped cheek appearance) on the face is highly characteristic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10196=[""].join("\n");
var outline_f9_61_10196=null;
var title_f9_61_10197="Basiliximab: Patient drug information";
var content_f9_61_10197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Basiliximab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     see \"Basiliximab: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/58/28582?source=see_link\">",
"     see \"Basiliximab: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Simulect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Simulect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will have more chance of getting infections. Avoid crowds and people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep the body from harming the organ after an organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat graft versus host effects after a bone marrow transplant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to basiliximab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697719",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust before care begins, during care, and for 4 months after care ends.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair growth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. This may get better once you are on a stable dose of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697962",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in look of teeth or gums.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Confusion; very nervous; anger with sweating, shivering, stiffness, or shaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12526 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-658DE962AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10197=[""].join("\n");
var outline_f9_61_10197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139095\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139096\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029007\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029009\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029008\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029012\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029013\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029015\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029011\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029016\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029017\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=related_link\">",
"      Basiliximab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/58/28582?source=related_link\">",
"      Basiliximab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_61_10198="Percutaneous pulmonic valve implantation";
var content_f9_61_10198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Percutaneous pulmonic valve implantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10198/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10198/contributors\">",
"     Sohrab Fratz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10198/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10198/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10198/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10198/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/61/10198/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H354444672\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous pulmonic valve implantation (PPVI) was developed as a nonsurgical treatment for patients with right ventricular outflow tract (RVOT) dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/1\">",
"     1",
"    </a>",
"    ]. PPVI devices are intended for use in a dysfunctional (stenotic or regurgitant) right ventricle-to-pulmonary artery conduit. PPVI is intended to extend the lifetime of a right ventricle-to-pulmonary artery conduit and hence reduce the total number of open-heart surgeries required over a patient&rsquo;s lifetime.",
"   </p>",
"   <p>",
"    Some centers have extended the application of PPVI to treat patients with tetralogy of Fallot without a conduit [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and to treat patients with tetralogy of Fallot with failing pulmonic bioprosthetic valves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444679\">",
"    <span class=\"h1\">",
"     INDICATIONS AND EXCLUSIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7138946\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend PPVI for patients with right ventricle to pulmonary artery conduits, native right ventricle outflow tracts, or failing bioprosthetic valves in the pulmonary position meeting the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe RVOT obstruction",
"      <strong>",
"       or",
"      </strong>",
"      severe pulmonic regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In cases with predominant RVOT obstruction and no or mild pulmonary regurgitation, the patient should have either of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms related to RVOT obstruction (&lt;65 percent of expected exercise tolerance) plus a peak continuous wave Doppler velocity of &gt;3.5",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     or",
"    </strong>",
"   </p>",
"   <p>",
"    No symptoms plus RVOT obstruction with peak continuous wave Doppler velocity &gt;4.0",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"    <strong>",
"     or",
"    </strong>",
"    RVOT obstruction with right ventricular systolic pressure greater than two-thirds of systemic systolic pressure",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In cases with predominant pulmonary regurgitation and little or no RVOT obstruction, the patient should have severe pulmonary regurgitation with right ventricular end-diastolic volume index &gt;150",
"      <span class=\"nowrap\">",
"       cm/m&sup2;",
"      </span>",
"      by cardiovascular magnetic resonance imaging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adequate RVOT conduit size to accommodate a covered stent. We do not have a lower size limitation. The upper size limitation is usually a diameter &lt;26 mm, in selected cases &lt;29 mm.",
"     </li>",
"     <li>",
"      There is no absolute lower age limit but an adequate body size (eg, weight &gt;20 kg) is required to accommodate femoral placement of the introducer [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following exclusion criteria are adapted from the 2010 European Society of Cardiology guidelines for the management of grown-up congenital heart disease endorsed by the Association for European Pediatric Cardiology (AEPC) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of risk of coronary compression by the expanded implant as determined by balloon testing [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Central vein occlusion or significant obstruction",
"     </li>",
"     <li>",
"      Active infection (such as endocarditis) or high risk of infection (such as intravenous drug abuse)",
"     </li>",
"     <li>",
"      Surgery is preferred when additional interventions are considered such as tricuspid annuloplasty, coronary artery bypass, or arrhythmia surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354445416\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 European Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ESC)/Association",
"    </span>",
"    for European Pediatric Cardiology (AEPC) guidelines for the management of grown-up congenital heart disease include the following indications for surgical intervention or PPVI in patients with right ventricular to pulmonary artery conduits [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intervention is recommended in symptomatic patients with RV systolic pressure &gt;60 mmHg (TR velocity &gt;3.5",
"      <span class=\"nowrap\">",
"       m/s;",
"      </span>",
"      may be lower in cases with reduced flow)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      moderate to severe pulmonic regurgitation.",
"     </li>",
"     <li>",
"      Intervention is suggested in asymptomatic patients with severe right ventricular outflow tract obstruction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe pulmonic regurgitation when at least one of the following criteria is present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Decrease in exercise capacity on cardiopulmonary exercise testing",
"     </li>",
"     <li>",
"      Progressive RV dilation",
"     </li>",
"     <li>",
"      Progressive RV systolic dysfunction",
"     </li>",
"     <li>",
"      Progressive TR (at least moderate)",
"     </li>",
"     <li>",
"      RV systolic pressure &gt;80 mmHg (TR velocity &gt;4.3",
"      <span class=\"nowrap\">",
"       m/s)",
"      </span>",
"     </li>",
"     <li>",
"      Sustained",
"      <span class=\"nowrap\">",
"       atrial/ventricular",
"      </span>",
"      arrhythmias",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444694\">",
"    <span class=\"h1\">",
"     IMPLANTATION TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two different types of valves are commercially available for PPVI, the Medtronic Melody Transcatheter Pulmonary Valve and the Edwards SAPIEN Pulmonic Transcatheter Heart Valve.",
"   </p>",
"   <p>",
"    The implantation technique for the two valves for PPVI is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/1,6,9-13\">",
"     1,6,9-13",
"    </a>",
"    ]. PPVI is usually performed using general endotracheal anesthesia, although use of conscious sedation has been reported. Venous access is generally obtained through the femoral vein, although a jugular venous approach is also feasible. After a complete hemodynamic and angiographic study, a guidewire is positioned distally into a pulmonary artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10923124\">",
"    <span class=\"h2\">",
"     Balloon test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because coronary compression is a serious complication of PPVI, a balloon test to exclude potential coronary artery compression should always be performed. This involves inflation of a high pressure balloon in the RVOT conduit. During balloon inflation, an aortogram is obtained to display the coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/9\">",
"     9",
"    </a>",
"    ]. If coronary artery flow is impaired during this test, PPVI should not be performed. For this test, an aortogram may be preferable to selective coronary artery angiogram because intubation of the coronary artery by the catheter may lead to a false negative test (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef88691 \" href=\"UTD.htm?39/4/40003\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10923131\">",
"    <span class=\"h2\">",
"     Pre-stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have found that pre-stenting of the conduit before PPVI is associated with a lower risk of developing PPVI stent fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, pre-stenting of the conduit before PPVI is now standard practice in most centers. Usually, a covered bare metal stent is preferred to avoid bleeding out of the ruptured conduit during deployment of the stent, because high-pressure balloons are needed to dilate the conduit to the previously tested diameter. In some cases (eg, long stenosis or significant recoil during balloon deflation), additional stents are needed for pre-stenting. A non-covered stent is usually used if obstruction of the origin of one of the pulmonary branch arteries (&ldquo;jailing&rdquo;) is expected after deployment of the pre-stent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10923138\">",
"    <span class=\"h2\">",
"     Valve types",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the final diameter of the treated right ventricular outflow tract, either a Melody valve (18 to 22 mm) or a Sapien valve (23 or 26 mm) is chosen.",
"   </p>",
"   <p>",
"    The Medronic Melody Transcatheter Pulmonary Valve is available in one size and can be implanted with a diameter of 18, 20, or 22 mm. The Melody valve consists of a 34 mm bare metal Cheatham platinum stent (NuMED CP Stent CP8Z34) into which a Medtronic Contegra bovine jugular venous valve is hand-sewn. The valve is crimped onto a designated double balloon delivery system requiring a 22 F sheath.",
"   </p>",
"   <p>",
"    The Edwards SAPIEN Pulmonic Transcatheter Heart Valve is available in two sizes, 23 and 26 mm. The Sapien&reg; valve is made of a trileaflet bovine pericardial valve hand-sewn into a stainless-steel stent. There is a fabric sealing cuff covering the proximal part of the stent designed to prevent paravalvular leaking. The valve is crimped onto a designated balloon delivery system requiring a 22 F or 24 F sheath for the 23 or 26 mm valve, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444715\">",
"    <span class=\"h2\">",
"     Valve-in-valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPVI can also be performed as a repeat intervention after failure of the primary device in the RVOT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/15\">",
"     15",
"    </a>",
"    ]. The indications and the implantation technique are the same for repeat PPVI as for primary PPVI. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444722\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short- and medium-term results of PPVI with the Melody and Sapien valves are similar though more data are available for the Melody valve. Long-term outcome data are not yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444730\">",
"    <span class=\"h2\">",
"     Melody valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparison studies with conventional surgery are lacking. Data are available from four short- and medium-term observational studies with a total of over 450 patients with one- to five-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/6,7,16,17\">",
"     6,7,16,17",
"    </a>",
"    ]. These studies excluded 4 to 8 percent of the patients planned for PPVI due to an unfavorable right ventricular outflow tract dimension or coronary artery compression.",
"   </p>",
"   <p>",
"    After successful PPVI, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall mortality was 0 to 5 percent and was, as far as could be assessed, not related to the PPVI.",
"     </li>",
"     <li>",
"      The gradient over the right ventricular outflow tract fell significantly from median values of 35 to 40 to 10 to 20 mmHg.",
"     </li>",
"     <li>",
"      The device was unstable in 1 percent, a conduit rupture requiring surgery occurred in 0.8 to 2 percent, compression of the left main coronary artery after device deployment occurred in 0 to 1 percent, and obstruction of the origin of one of the pulmonary branch arteries (&ldquo;jailing&rdquo;) in 0.6 percent. Overall, surgery was required in 3 percent during follow-up with a freedom from reoperation of 86 percent at 30 months.",
"     </li>",
"     <li>",
"      Freedom from Melody valve dysfunction or reintervention was 94 to 95 percent at one year. Patients not requiring reintervention had mild or less pulmonic valve regurgitation at one-year follow-up. Pulmonary regurgitation decreased from median values of 16 to 27 percent to 1 to 2 percent. Median peak velocity over the right ventricular outflow tract was 1.9 to 2.7",
"      <span class=\"nowrap\">",
"       m/s",
"      </span>",
"      at one-year echocardiographic follow-up.",
"     </li>",
"     <li>",
"      Six months post-operatively, RV end-diastolic volume and RV mass decreased significantly as demonstrated by cardiovascular magnetic resonance imaging.",
"     </li>",
"     <li>",
"      Endocarditis was diagnosed in 1 to 3 percent of the cases up to five years after PPVI. At six months, NYHA class improved in 77 percent of the patients and worsened only in 0.8 percent.",
"     </li>",
"     <li>",
"      Stent fractures occurred in 20 to 21 percent in a series without pre-stenting and in 5 to 16 percent in a series with pre-stenting.",
"     </li>",
"     <li>",
"      In an early study, the first 50 patients of the series and those with residual gradients &gt;25 mmHg had a higher risk of reoperations compared to the rest of the study group [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444737\">",
"    <span class=\"h2\">",
"     Sapien valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparison studies with conventional surgery are lacking. Data are available from two short- and medium-term observational studies with a total of 43 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In the larger series of 36 patients, successful valve deployment was achieved in 33 of 34 attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/13\">",
"     13",
"    </a>",
"    ]. Pullback peak-to-peak systolic gradient across the conduit decreased from 27 to 12 mmHg. At six months follow-up, the number of patients in New York Heart Association functional class I increased from 5 at baseline to 27. Pulmonic regurgitation was moderate or less in 97 percent of patients. One patient was treated with a second valve due to conduit-induced distortion of the initial implant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444751\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354445432\">",
"    <span class=\"h2\">",
"     Coronary artery compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression of the left main coronary artery after device deployment occurs in approximately 0 to 1 percent of all cases of PPVI and has nearly always a fatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/6,7,16,17\">",
"     6,7,16,17",
"    </a>",
"    ]. Therefore, a balloon test to exclude potential coronary artery compression should always be performed prior to deployment of the valve [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/9\">",
"     9",
"    </a>",
"    ]. A balloon test positive for coronary artery compression occurs in about 1 percent of all cases referred to PPVI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10923124\">",
"     'Balloon test'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Rarely, hematoma formation from conduit laceration may cause acute extrinsic coronary artery compression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444759\">",
"    <span class=\"h2\">",
"     Conduit rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of conduit rupture is always needed to relieve conduit stenosis. Conduit rupture requiring surgery occurs in about 0.8 to 2 percent of all cases of PPVI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/6,7,16\">",
"     6,7,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444766\">",
"    <span class=\"h2\">",
"     Stent fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent fractures occur in 20 to 21 percent with no pre-stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/7,16\">",
"     7,16",
"    </a>",
"    ] and in 5 to 16 percent with pre-stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. In the majority of cases, stent fractures have no significant hemodynamic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/19\">",
"     19",
"    </a>",
"    ]. However, stent fractures may ultimately lead to stent embolization or restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/16\">",
"     16",
"    </a>",
"    ]. Observational data suggest that pre-stenting reduces the risk of stent fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. Therefore, pre-stenting of the conduit with a bare metal stent before PPVI is now standard practice in most centers. (See",
"    <a class=\"local\" href=\"#H10923131\">",
"     'Pre-stenting'",
"    </a>",
"    above.) Other risk factors associated with stent fractures are severely obstructed conduits, PPVI into a native outflow tract, and presence of PPV recoil during balloon deflation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444773\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocarditis after PPVI has been observed in approximately 1 to 3 percent of patients during one- to four-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/6,7,16,17\">",
"     6,7,16,17",
"    </a>",
"    ]. This rate is similar to the observed rate of endocarditis after surgical right ventricular outflow tract reconstruction of approximately 0 to 5 percent of patients during one- to four-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10198/abstract/21-28\">",
"     21-28",
"    </a>",
"    ]. Trials directly comparing the incidence of endocarditis with the two techniques are lacking.",
"   </p>",
"   <p>",
"    All patients with prosthetic valves, including those who have undergone PPVI are considered among those at highest risk for endocarditis and therefore prophylaxis for bacterial endocarditis is suggested for high risk procedures such as all dental procedures that involve manipulation of gingival tissue, the periapical region of teeth, or perforation of the oral mucosa. Recommendations for antibiotic prophylaxis for endocarditis are discussed in detail separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354444780\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Percutaneous pulmonic valve implantation (PPVI) is an effective treatment for selected patients with right ventricular outflow tract (RVOT) conduit (or native) stenosis or regurgitation. Short- and mid-term results are satisfactory, while long-term results and direct comparison with conventional surgery are not yet available. (See",
"      <a class=\"local\" href=\"#H354444722\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend PPVI in selected patients with severe RVOT obstruction",
"      <strong>",
"       or",
"      </strong>",
"      severe pulmonary regurgitation. (See",
"      <a class=\"local\" href=\"#H7138946\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common complication following PPVI is stent fracture which usually is hemodynamically benign. Uncommon complications occurring in 2 percent or less of patients include clinically significant conduit rupture, coronary artery compression, and endocarditis. (See",
"      <a class=\"local\" href=\"#H354444751\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since coronary compression is a life-threatening complication of PPVI, a balloon test is performed in the right ventricular outflow tract to exclude potential coronary artery compression (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef88691 \" href=\"UTD.htm?39/4/40003\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H354444694\">",
"       'Implantation technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H354445432\">",
"       'Coronary artery compression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/1\">",
"      Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 2000; 356:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/2\">",
"      Momenah TS, El Oakley R, Al Najashi K, et al. Extended application of percutaneous pulmonary valve implantation. J Am Coll Cardiol 2009; 53:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/3\">",
"      Boudjemline Y, Brugada G, Van-Aerschot I, et al. Outcomes and safety of transcatheter pulmonary valve replacement in patients with large patched right ventricular outflow tracts. Arch Cardiovasc Dis 2012; 105:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/4\">",
"      Gillespie MJ, Rome JJ, Levi DS, et al. Melody valve implant within failed bioprosthetic valves in the pulmonary position: a multicenter experience. Circ Cardiovasc Interv 2012; 5:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/5\">",
"      Eicken A, Hess J. Percutaneous pulmonary valve implantation: the Munich experience. Interventional Cardiology 2012; 4:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/6\">",
"      Eicken A, Ewert P, Hager A, et al. Percutaneous pulmonary valve implantation: two-centre experience with more than 100 patients. Eur Heart J 2011; 32:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/7\">",
"      McElhinney DB, Hellenbrand WE, Zahn EM, et al. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. Circulation 2010; 122:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/8\">",
"      Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/9\">",
"      Sridharan S, Coats L, Khambadkone S, et al. Images in cardiovascular medicine. Transcatheter right ventricular outflow tract intervention: the risk to the coronary circulation. Circulation 2006; 113:e934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/10\">",
"      Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial. J Am Coll Cardiol 2009; 54:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/11\">",
"      Garay F, Webb J, Hijazi ZM. Percutaneous replacement of pulmonary valve using the Edwards-Cribier percutaneous heart valve: first report in a human patient. Catheter Cardiovasc Interv 2006; 67:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/12\">",
"      Boone RH, Webb JG, Horlick E, et al. Transcatheter pulmonary valve implantation using the Edwards SAPIEN transcatheter heart valve. Catheter Cardiovasc Interv 2010; 75:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/13\">",
"      Kenny D, Hijazi ZM, Kar S, et al. Percutaneous implantation of the Edwards SAPIEN transcatheter heart valve for conduit failure in the pulmonary position: early phase 1 results from an international multicenter clinical trial. J Am Coll Cardiol 2011; 58:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/14\">",
"      Nordmeyer J, Lurz P, Khambadkone S, et al. Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation: acute and 1-year outcomes. Heart 2011; 97:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/15\">",
"      Nordmeyer J, Coats L, Lurz P, et al. Percutaneous pulmonary valve-in-valve implantation: a successful treatment concept for early device failure. Eur Heart J 2008; 29:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/16\">",
"      Lurz P, Coats L, Khambadkone S, et al. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome. Circulation 2008; 117:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/17\">",
"      Butera G, Milanesi O, Spadoni I, et al. Melody transcatheter pulmonary valve implantation. Results from the registry of the Italian society of pediatric cardiology. Catheter Cardiovasc Interv 2013; 81:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/18\">",
"      Mauri L, Frigiola A, Butera G. Emergency surgery for extrinsic coronary compression after percutaneous pulmonary valve implantation. Cardiol Young 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/19\">",
"      Nordmeyer J, Khambadkone S, Coats L, et al. Risk stratification, systematic classification, and anticipatory management strategies for stent fracture after percutaneous pulmonary valve implantation. Circulation 2007; 115:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/20\">",
"      McElhinney DB, Cheatham JP, Jones TK, et al. Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial. Circ Cardiovasc Interv 2011; 4:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/21\">",
"      Corno AF, Hurni M, Griffin H, et al. Bovine jugular vein as right ventricle-to-pulmonary artery valved conduit. J Heart Valve Dis 2002; 11:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/22\">",
"      Breymann T, Boethig D, Goerg R, Thies WR. The Contegra bovine valved jugular vein conduit for pediatric RVOT reconstruction: 4 years experience with 108 patients. J Card Surg 2004; 19:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/23\">",
"      Bov&eacute; T, Demanet H, Wauthy P, et al. Early results of valved bovine jugular vein conduit versus bicuspid homograft for right ventricular outflow tract reconstruction. Ann Thorac Surg 2002; 74:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/24\">",
"      Carrel T, Berdat P, Pavlovic M, Pfammatter JP. The bovine jugular vein: a totally integrated valved conduit to repair the right ventricular outflow. J Heart Valve Dis 2002; 11:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/25\">",
"      Boudjemline Y, Bonnet D, Massih TA, et al. Use of bovine jugular vein to reconstruct the right ventricular outflow tract: early results. J Thorac Cardiovasc Surg 2003; 126:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/26\">",
"      Tiete AR, Sachweh JS, Roemer U, et al. Right ventricular outflow tract reconstruction with the Contegra bovine jugular vein conduit: a word of caution. Ann Thorac Surg 2004; 77:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/27\">",
"      Meyns B, Van Garsse L, Boshoff D, et al. The Contegra conduit in the right ventricular outflow tract induces supravalvular stenosis. J Thorac Cardiovasc Surg 2004; 128:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10198/abstract/28\">",
"      Shebani SO, McGuirk S, Baghai M, et al. Right ventricular outflow tract reconstruction using Contegra valved conduit: natural history and conduit performance under pressure. Eur J Cardiothorac Surg 2006; 29:397.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86481 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10198=[""].join("\n");
var outline_f9_61_10198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H354444780\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H354444672\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H354444679\">",
"      INDICATIONS AND EXCLUSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7138946\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354445416\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H354444694\">",
"      IMPLANTATION TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10923124\">",
"      Balloon test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10923131\">",
"      Pre-stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10923138\">",
"      Valve types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354444715\">",
"      Valve-in-valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H354444722\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354444730\">",
"      Melody valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354444737\">",
"      Sapien valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H354444751\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354445432\">",
"      Coronary artery compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354444759\">",
"      Conduit rupture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354444766\">",
"      Stent fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354444773\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H354444780\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/86481\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/86481|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/4/40003\" title=\"diagnostic image 1\">",
"      Balloon test prior to PPVI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_61_10199="Elliptocytes";
var content_f9_61_10199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elliptical red cells in hereditary elliptocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with hereditary elliptocytosis shows multiple elliptocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10199=[""].join("\n");
var outline_f9_61_10199=null;
var title_f9_61_10200="Thyroid hormone action";
var content_f9_61_10200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thyroid hormone action",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10200/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10200/contributors\">",
"     Gregory A Brent, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10200/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10200/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/61/10200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormones are critical determinants of brain and somatic development in infants and of metabolic activity in adults; they also affect the function of virtually every organ system. Thyroid hormones must be constantly available to perform these functions. To maintain their availability, there are large stores of thyroid hormone in the thyroid gland. Furthermore, thyroid hormone biosynthesis and secretion are maintained within narrow limits by a regulatory mechanism that is very sensitive to small changes in circulating hormone concentrations.",
"   </p>",
"   <p>",
"    Thyroid hormone, in the form of triiodothyronine (T3), acts by modifying gene transcription in virtually all tissues to alter rates of protein synthesis and substrate turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These actions are the net result of the presence of T3 and of multiple other factors that amplify or reduce its action (",
"    <a class=\"graphic graphic_figure graphicRef62658 graphicRef75347 \" href=\"UTD.htm?40/11/41151\">",
"     figure 1A-B",
"    </a>",
"    ). The actions of T3 will be reviewed here. The production of T3 and its precursor thyroxine (T4) and how their production is regulated are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .) Extranuclear actions of T4 and T3 have been increasingly recognized and are mediated by interactions with membranes receptors, organelles, and components of the signal transduction system [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF T3 ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nuclear actions of T3 are dependent upon four factors: the availability of the hormone, thyroid hormone nuclear receptors, receptor cofactors, and DNA regulatory elements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ligand availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone synthesis and secretion from the thyroid gland are regulated by pituitary thyrotropin (TSH). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .) Circulating T4 and T3 enter cells by diffusion and, in some tissues, such as the brain, by active transport [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/5\">",
"     5",
"    </a>",
"    ]. An inherited defect in the MCT8 thyroid transporter has been associated with alterations of circulating thyroid hormone levels and severely impaired neurologic development in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/6\">",
"     6",
"    </a>",
"    ]. T3 is also available to cells because it is produced from T4 within them. The locally produced T3, some of which leaves the cells, provides much of the T3 that is bound to T3 nuclear receptors in many tissues. Overall, about 80 percent of circulating T3 in humans is derived from extrathyroidal conversion of T4 to T3, and about 20 percent from direct thyroidal secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The regulation of T3 production at the tissue level is increasingly recognized as an important influence on thyroid hormone action. The fraction of T3 that is produced locally from T4, and the contribution of locally produced T3 to the amount of T3 bound to its receptors vary substantially by species and from tissue to tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/8\">",
"     8",
"    </a>",
"    ]. In humans, approximately 80 percent of extrathyroidal T3 produced from T4 is produced intracellularly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thyroid hormone nuclear receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two thyroid hormone nuclear receptors (TR), alpha and beta (",
"    <a class=\"graphic graphic_figure graphicRef70770 \" href=\"UTD.htm?36/4/36928\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. They are encoded by separate genes located respectively on chromosomes 17 and 3. TR-alpha and -beta are structurally similar; as a result of alternative splicing, there are multiple forms of each, TR-alpha-1 and -2 and TR-beta-1, -2, and -3. T3 binds to these TRs, with the exception of TR-alpha-2, and the T3-TR complexes then bind to regulatory regions contained in the genes that are responsive to thyroid hormone (",
"    <a class=\"graphic graphic_figure graphicRef62658 \" href=\"UTD.htm?9/40/9870\">",
"     figure 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75347 \" href=\"UTD.htm?20/33/21022\">",
"     figure 1B",
"    </a>",
"    ). TRs without T3 bind to nuclear receptor compressors and then to regulatory regions of genes normally induced by T3, resulting in repression of gene expression.",
"   </p>",
"   <p>",
"    The TR isoforms contain separate domains that bind T3, DNA, and form dimers with TR molecules, as well as other receptors such as retinoid X receptors (RXRs), which bind 9-cis retinoic acid (",
"    <a class=\"graphic graphic_figure graphicRef70770 \" href=\"UTD.htm?36/4/36928\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/10\">",
"     10",
"    </a>",
"    ]. The predominant functional unit for T3 gene regulation is a",
"    <span class=\"nowrap\">",
"     TR/RXR",
"    </span>",
"    heterodimer (",
"    <a class=\"graphic graphic_figure graphicRef62658 \" href=\"UTD.htm?9/40/9870\">",
"     figure 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75347 \" href=\"UTD.htm?20/33/21022\">",
"     figure 1B",
"    </a>",
"    ). The influence of RXR on the nuclear receptor complex varies depending on its receptor partner, but thyroid hormone is the major influence on the activity of the",
"    <span class=\"nowrap\">",
"     TR/RXR",
"    </span>",
"    heterodimer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Receptor cofactors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a large family of regulatory proteins that interact directly with TR to augment or inhibit the response to T3 (see",
"    <a class=\"local\" href=\"#H12\">",
"     'TR cofactors'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     DNA regulatory elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 5'-flanking region (located upstream of the transcription start site) of thyroid hormone-responsive genes contains specific DNA sequences that bind",
"    <span class=\"nowrap\">",
"     TR/RXR",
"    </span>",
"    heterodimers, thereby altering gene expression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THYROID HORMONE ACTIONS DURING DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone has important effects on neural and somatic development, both during fetal life and the first years of postnatal life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ligand availability during fetal development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal thyroid gland begins to function at 10 to 12 weeks of gestation, and is the primary source of thyroid hormone in the developing fetus after the first trimester, during which maternal thyroxine is the only source. In congenital hypothyroidism, where the fetus makes no thyroid hormone, sufficient maternal T4 crosses the placenta to the fetus for normal in utero development (or nearly so) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/11\">",
"     11",
"    </a>",
"    ]. In severe iodine deficiency, which is associated with both maternal and fetal hypothyroidism, fetal development is not normal, and the changes are not reversible with postnatal thyroid hormone therapy. Women who are hypothyroid during pregnancy have an increased risk of miscarriage and preterm delivery and some mild intellectual impairment in their offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Hypothyroidism during pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40696?source=see_link\">",
"     \"Thyroid physiology and screening in preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Expression pattern of TR isoforms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of TR-isoform expression is similar among the different species in which it has been studied, and it differs in fetal and adult tissues (",
"    <a class=\"graphic graphic_figure graphicRef74930 \" href=\"UTD.htm?5/50/5935\">",
"     figure 3",
"    </a>",
"    ). TR-alpha, especially the TR-alpha-2 isoform, is expressed first. TR-beta appears later, usually detected at the time T3 is first produced. Both TR-alpha and -beta are functional, although the timing and pattern of expression suggest specific roles in development. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Tissue-specific expression of TR isoforms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TISSUE-SPECIFIC THYROID HORMONE ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;T3 has different actions in different tissues. These differences are determined by variations in both local production of T3 and the tissue distribution and content of TR isoforms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tissue-specific expression of TR isoforms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variable expression of the isoforms of TR-alpha and -beta in tissues has been characterized (",
"    <a class=\"graphic graphic_figure graphicRef74930 \" href=\"UTD.htm?5/50/5935\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/13\">",
"     13",
"    </a>",
"    ]. Liver, muscle, and kidney contain predominantly TR-beta, whereas the heart contains similar amounts of TR-alpha and -beta. The brain contains predominantly TR-alpha, but TR-beta-2 is present in high levels in some areas of the brain, especially in the hypothalamus and pituitary, and has a special role in regulation of genes negatively regulated by T3, such as the genes for thyrotropin-releasing hormone (TRH) and the subunits of TSH. Even within a tissue (as an example, bone or brain) there is region- or cell-specific distribution of TR isoforms, suggesting that the different TR isoforms have different functions.",
"   </p>",
"   <p>",
"    Most of what is known about the role of the individual TR isoforms comes from gene-deletion (knockout) and TR gene point mutation studies in mice (",
"    <a class=\"graphic graphic_table graphicRef54862 \" href=\"UTD.htm?21/41/22172\">",
"     table 1",
"    </a>",
"    ). In these studies, mice are created from embryonic stem cells in which the TR alpha or beta gene is deleted or mutated and the resulting mice have the abnormality. The function of the gene is determined based on the phenotype of the genetically altered mice as compared with normal (wild-type) mice [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TR-alpha gene knockout and point mutation mice &mdash; Mice with TR-alpha deletion have poor feeding and growth, reduced bone mineralization, low basal body temperature, and slowed heart rate. Changes in thyroid function include low serum TSH and T4 concentrations. Mice heterozygous for dominant negative point mutations, analogous to those identified in TR-beta gene associated with resistance to thyroid hormone, have a phenotype generally similar to the TR-alpha homozygous deletions [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/15\">",
"       15",
"      </a>",
"      ]. Additional abnormalities that have been reported in mice with dominant negative TR-alpha mutations include defects in neurological development, impaired adaptive thermogenesis, and in one TR-alpha mutation, obesity and impaired lipolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TR-beta gene knockout and point mutation mice &mdash; Inactivation of the TR-beta gene is associated with thyroid-gland hyperplasia, high serum T4 concentrations, and inappropriately normal serum TSH concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/13,14\">",
"       13,14",
"      </a>",
"      ], similar to the clinical features of patients with resistance to thyroid hormone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link\">",
"       \"Resistance to thyrotropin and thyrotropin-releasing hormone\"",
"      </a>",
"      .) Other findings include hearing loss, which correlates well with the expression of TR-beta in the developing cochlea in normal mice, and tachycardia. Survival is normal. Mice heterozygous for point mutations in the TR-beta gene, modeled after those seen in resistance to thyroid hormone, have a similar phenotype to mice homozygous for TR-beta deletion.",
"      <br/>",
"      <br/>",
"      Both TSH secretion in response to hypothyroidism and T3 suppression of TSH secretion is impaired in these mice. These results indicate that TR-beta plays an important role in ligand-independent increase and T3-mediated suppression of TSH.",
"     </li>",
"     <li>",
"      Combined&nbsp;TR-alpha and -beta knockout mice &mdash; Mice in which both TR-alpha and -beta genes are deleted have marked thyroid hyperplasia and high serum concentrations of T4 (11 times greater than normal), T3 (30 times greater than normal), and TSH (up to 160 times greater than normal) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/17\">",
"       17",
"      </a>",
"      ]. They grow poorly, the pituitary content of growth hormone mRNA and growth hormone is low, and they have low serum insulin-like growth factor-1 concentrations. Bone development and mineralization are defective, and the epiphyseal plates are disorganized. Fertility is severely impaired in the females. Lifespan is reduced; about 30 percent of the mice die by nine months of age, as compared with no deaths among wild-type mice at this age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Important target tissues for thyroid hormone during development include bone, pituitary, small intestine, and the inner ear (",
"    <a class=\"graphic graphic_table graphicRef51065 \" href=\"UTD.htm?13/35/13883\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     TR cofactors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene activation or repression mediated by TRs also involves the interactions of TRs with other protein cofactors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These proteins, termed coactivators and corepressors, promote or impair interaction of TR with the basal transcription machinery (",
"    <a class=\"graphic graphic_figure graphicRef62658 graphicRef75347 \" href=\"UTD.htm?40/11/41151\">",
"     figure 1A-B",
"    </a>",
"    ). Many of these cofactors interact with steroid hormone and retinoid receptors in addition to TRs. Examples of coactivators are SRC (steroid receptor coactivator) and CBP (CREB [cAMP response element-binding protein] binding-protein). Examples of corepressors are NCoR (nuclear corepressor) and SMRT (silencing mediator of retinoid and thyroid receptors).",
"   </p>",
"   <p>",
"    In general, corepressors bind to TR in the absence of T3 and repress gene expression. T3 binding to TR displaces corepressor bound to TR and promotes binding of coactivator to promote gene activation. Some TR mutations associated with thyroid hormone resistance, all of which affect TR-beta, result in production of TRs with decreased affinity for these coactivators [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of animal and human studies suggest that these receptor coactivators and corepressors play essential roles in development and hormone action. Knockout of the SRC and CBP genes is lethal in fetal or neonatal life. These findings indicate the essential nature of these cofactors for development, but do not provide information on what genes are most affected when the cofactors are absent. An example of the role of a cofactor in thyroid hormone regulation is SRC. Mice with SRC gene deletion have high serum TSH and T4 concentrations, which increase readily in response to hypothyroidism but do not decrease normally in response to exogenous T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 10 percent of patients with thyroid hormone resistance do not have TR mutations, and may have cofactor gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=see_link\">",
"     \"Resistance to thyrotropin and thyrotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     DNA response elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;All genes regulated by T3 have specific sequences of DNA that bind TR with high affinity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Most of these sequences, known as thyroid hormone-response elements, consist of two tandemly arranged hexamer (or octamer) motifs with a consensus sequence of AGGTCA to which",
"    <span class=\"nowrap\">",
"     T3-TR/RXR",
"    </span>",
"    heterodimers bind, separated by four base pairs. Response elements are contained in the 5'-flanking regulatory region of the gene, but can be located throughout the gene including in introns and flanking sequences.",
"   </p>",
"   <p>",
"    The configurations of response elements that confer T3-dependent gene activation have been well characterized, and preferentially bind",
"    <span class=\"nowrap\">",
"     T3-TR/RXR",
"    </span>",
"    heterodimers. A single octameric sequence, TAAGGTCA, can also bind TR-TR dimers and confer positive gene regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Response elements that mediate gene repression have been more difficult to identify, and some appear to bind only T3-TR monomers. It is likely that negative regulation involves interaction with other transcription factors.",
"   </p>",
"   <p>",
"    In all genes transcriptionally regulated by T3, it should be possible to identify a DNA sequence that confers this regulation. With the availability of DNA sequence data from the human genome project, it is possible to identify T3-regulated genes based upon sequence inspection. Direct approaches to screen for sequences that bind receptors are available and have been utilized to identify genes regulated by related hormones, such as estrogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tissue-specific expression of thyroid hormone deiodinases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deiodinases that convert the prohormone T4 to the active hormone T3 and convert T3 to diiodothyronines are expressed in a development- and tissue-specific pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 5'-deiodinase (D1) is expressed predominantly in liver, kidneys, and muscle. In rodents, this enzyme is the primary source of circulating T3. D1 activity is reduced in hypothyroidism.",
"     </li>",
"     <li>",
"      Type 2 5'-deiodinase (D2) is expressed primarily in brown fat, pituitary, and cerebral cortex in rodents. It is more widely expressed in humans, including the thyroid, heart, and skeletal muscle, and produces the majority of circulating T3 in humans. D2 activity is increased in hypothyroidism and iodine deficiency.",
"     </li>",
"     <li>",
"      Type 3 5-deiodinase (D3) inactivates T4 and is expressed in placenta, developing brain, and skin. Developmentally, this is the first deiodinase expressed, and expression falls as expression of the other two deiodinases increases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Type 3 deiodinase (D3) appears to play a critical role in the maturation and function of the thyroid axis. This was illustrated by a D3 knockout mouse model where neonatal thyrotoxicosis followed by central hypothyroidism was observed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     THYROID HORMONE ACTION IN BONE, HEART, AND REGULATION OF METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major targets of thyroid hormone are the skeleton, the heart, and the metabolic regulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bone and bone development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with congenital hypothyroidism who are not treated have disordered and delayed epiphyseal development and grow poorly, as do some infants with thyroid hormone resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/21\">",
"     21",
"    </a>",
"    ]. Abnormal bone development is also a major feature of TR-alpha and combined TR",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    knockout mice (",
"    <a class=\"graphic graphic_table graphicRef54862 \" href=\"UTD.htm?21/41/22172\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. All TR isoforms are expressed in bone, and probably interact with other nuclear receptors including those for vitamin D and retinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, relatively few T3-regulated genes have been identified in bone.",
"   </p>",
"   <p>",
"    Serum osteocalcin concentrations are correlated with thyroid status, and osteocalcin mRNA levels in bone are stimulated by T3 in a region-specific pattern, paralleling those areas such as the hip that are most susceptible to osteoporosis in patients with hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Thyroid hormone-mediated bone loss is the result of thyroid hormone receptor alpha enhancement of catecholamine action. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiac gene expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heart is a major target for thyroid hormone action [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Most patients with thyroid hormone resistance have tachycardia, indicating no cardiac resistance to T3. This observation is consistent with the fact that these patients have TR-beta mutations, since mice with TR-beta deletions do not show cardiac resistance to T3. In contrast, mice with TR-alpha deletions have bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/13\">",
"     13",
"    </a>",
"    ]. This is also consistent with the absence of tachycardia in patients treated with selective TR-beta agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Regulation of metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone regulates metabolic rate and is associated with modest changes in body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Animal models have demonstrated that TR-alpha is important for thyroid hormone-mediated enhancement of adrenergic action [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/16,24\">",
"     16,24",
"    </a>",
"    ]. Humans with thyroid hormone resistance associated with TR-beta mutations and elevated thyroid hormone levels have increased stimulation of TR-alpha. The metabolic phenotype of increased-TR alpha stimulation is increased feeding and increased fatty acid oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/24\">",
"     24",
"    </a>",
"    ]. Human studies have shown a direct connection between thyroid status and response to adrenergic stimulation in subcutaneous fat [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/29\">",
"     29",
"    </a>",
"    ]. The regulation of glucose uptake is more complex, but thyroid hormone promotes glucose uptake and polymorphisms in the D2 gene have been associated with glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/30\">",
"     30",
"    </a>",
"    ]. Impairment of mitochondrial oxidative metabolism, as is seen in type 2 diabetes and the metabolic syndrome, may be linked in some individuals to reduced thyroid hormone action [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/31\">",
"     31",
"    </a>",
"    ]. Thyroid hormone also regulates metabolism by interaction with other metabolic nuclear receptors such as PPAR alpha and LXR [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     AGENTS THAT MAY INTERFERE WITH THYROID HORMONE ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of drugs have been reported that can alter thyroxine absorption and metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/32\">",
"     32",
"    </a>",
"    ]. Agonists for retinoic acid receptor (RAR) and RXR, retinoids and rexinoids, suppress TSH and can produce central hypothyroidism in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/33\">",
"     33",
"    </a>",
"    ]. Agents that have been shown to interfere with thyroid hormone action include smoking cigarettes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/34\">",
"     34",
"    </a>",
"    ], and a range of environmental agents, especially polychlorinated biphenyls (PCBs) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/35\">",
"     35",
"    </a>",
"    ]. Iodine is concentrated in the thyroid gland by the action of the",
"    <span class=\"nowrap\">",
"     sodium/iodide",
"    </span>",
"    symporter (NIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/36\">",
"     36",
"    </a>",
"    ]. Agents that block NIS and iodine concentration include perchlorate, a contaminant of water and food in some regions, and thiocyanate, found in water and cigarette smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. Soy is frequently implicated, but there is no convincing evidence that soy protein or isoflavones interfere with thyroid hormone action in vivo&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/38\">",
"     38",
"    </a>",
"    ]. Soy protein, however, can interfere with thyroxine absorption from the intestine, which is especially important for infants with congenital hypothyroidism on thyroxine replacement and receiving soy-based formula [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of development- and tissue-specific pathways of thyroid hormone action is being translated into novel therapies. As an example, identification of the crystal structure of the ligand-binding domain of TRs has led to synthesis of novel analogues that are potential treatments for a variety of conditions, including hypercholesterolemia, hepatic steatosis, obesity, and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/24,39,40\">",
"     24,39,40",
"    </a>",
"    ]. A highly innovative use of thyroid hormone is the topical application of T3, shown in animal models to accelerate wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical markers of thyroid hormone action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of clinical assessment of thyroid status is measurement of serum TSH. Although this is the gene product regulated by thyroid hormone that is most easily measured, this does not necessarily mean that the intensity of action of thyroid hormone in other tissues is similar. As discussed previously, the tissue distribution of deiodinases varies, which means that local production of T3 may vary. Thus, there is the potential for disparity of T3 production and therefore action in different tissues.",
"   </p>",
"   <p>",
"    Other clinical markers of T3 action are serum sex hormone-binding globulin, osteocalcin, and angiotensin-converting enzyme concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/25\">",
"     25",
"    </a>",
"    ], all of which are increased by T3. Conversely, serum cholesterol concentrations are decreased by T3. However, none of these measurements is as sensitive to changes in serum T4 and T3 concentrations as are measurements of serum TSH. Based on animal studies, however, levels of gene products in specific thyroid hormone target tissues may give the best \"profile\" of tissue thyroid status, but this is not yet possible in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/13,24\">",
"     13,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Selective thyroid hormone analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many analogs of T4 and T3 have been synthesized in the hope of finding one that would have a desired effect of thyroid hormone, such as lowering serum cholesterol concentrations or stimulating energy expenditure, without having undesirable effects on the heart, skeletal muscle, or bone. In hypothyroid patients given doses of T4 and triiodothyroacetic acid (tiratricol) that have similar effects on TSH secretion, triiodothyroacetic acid resulted in lower serum cholesterol and higher sex hormone-binding globulin concentrations and greater increases in markers of bone formation and resorption, indicating some dissociation of effects on the pituitary, liver, and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The identification of the crystal structure of the ligand-binding domain of TRs has led directly to the design of agonists that selectively stimulate TR isoforms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. As an example, GC1, designed based on the crystal structure of the ligand-binding domain of the TRs, has a 10-fold higher affinity for TR-beta than for TR-alpha. In hypothyroid rats treated with equimolar doses of T3 or GC1, GC1 caused a greater reduction in serum triglyceride concentrations, equivalent reduction in serum cholesterol concentrations, and less stimulation of the heart (as assessed by heart rate and cardiac-specific gene expression). Treatment with GC1 at doses that produce bone resorption with T3 do not result in loss of bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, the compound KB-141, another TR-beta selective agonist, produced a marked reduction in weight, cholesterol, and Lp(a) in a primate model, with no other apparent side-effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypercholesterolemic patients not at LDL target levels while on statins were given eprotirome (KB2115), a TR-beta selective agonist. Treatment for 12 weeks resulted in reduced total and LDL-cholesterol in all patients and also reduced triglycerides in those individuals with elevated baseline triglyceride levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/45\">",
"     45",
"    </a>",
"    ]. Adverse effects on the heart or bone were not detected in this short study, although a transaminitis was seen in some patients and the levels of sex hormone binding globulin were significantly elevated. Expanded clinical trials with eprotirome are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H14#H14\">",
"     \"Lipid lowering with drugs other than statins and fibrates\", section on 'Thyromimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vascular system is being increasingly recognized as a therapeutic target for thyroid hormone and its analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/24,46\">",
"     24,46",
"    </a>",
"    ]. A cardio-selective thyroid hormone analog, DITPA, has had some utility in treatment of congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/47\">",
"     47",
"    </a>",
"    ], although a longer study resulted in significant toxicity, especially metabolic, and the trial was stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10200/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16987421\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormones are critical determinants of brain and somatic development in infants and of metabolic activity in adults; they also affect the function of virtually every organ system. Thyroid hormones must be constantly available to perform these functions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulating T4 and T3 enter cells by diffusion and in some tissues, such as the brain, by active transport. T3 is also available to cells because it is produced from T4 within them. The locally produced T3, some of which leaves the cells, provides much of the T3 that is bound to T3 nuclear receptors in many tissues. Overall, about 80 percent of circulating T3 in humans is derived from extrathyroidal conversion of T4 to T3, and about 20 percent from direct thyroidal secretion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ligand availability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two thyroid hormone nuclear receptors (TR), alpha and beta (",
"      <a class=\"graphic graphic_figure graphicRef70770 \" href=\"UTD.htm?36/4/36928\">",
"       figure 2",
"      </a>",
"      ). T3 binds to these TRs, and the T3-TR complexes then bind to regulatory regions contained in the genes that are responsive to thyroid hormone. TRs without T3 bind to nuclear receptor compressors and then to regulatory regions of genes normally induced by T3, resulting in repression of gene expression (",
"      <a class=\"graphic graphic_figure graphicRef62658 \" href=\"UTD.htm?9/40/9870\">",
"       figure 1A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75347 \" href=\"UTD.htm?20/33/21022\">",
"       figure 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thyroid hormone nuclear receptors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thyroid hormone, in the form of triiodothyronine (T3), acts by modifying gene transcription in virtually all tissues to alter rates of protein synthesis and substrate turnover. T3 has different actions in different tissues. These differences are determined by variations in both local production of T3 and the tissue distribution and content of TR isoforms (",
"      <a class=\"graphic graphic_table graphicRef51065 \" href=\"UTD.htm?13/35/13883\">",
"       table 2",
"      </a>",
"      ). The deiodinases that convert the prohormone T4 to the active hormone T3 and convert T3 to diiodothyronines are also expressed in a development- and tissue-specific pattern. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Tissue-specific thyroid hormone action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thyroid hormone has important effects on neural and somatic development, both during fetal life and the first years of postnatal life. Major targets of thyroid hormone are the skeleton, the heart, and the metabolic regulation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Thyroid hormone actions during development'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Thyroid hormone action in bone, heart, and regulation of metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The identification of development- and tissue-specific pathways of thyroid hormone action is being translated into novel therapies. As an example, identification of the crystal structure of the ligand-binding domain of TRs has led to synthesis of novel analogues that are potential treatments for a variety of conditions, including hypercholesterolemia, hepatic steatosis, obesity, and heart failure. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical applications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/1\">",
"      Brent GA. The molecular basis of thyroid hormone action. N Engl J Med 1994; 331:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/2\">",
"      Oetting A, Yen PM. New insights into thyroid hormone action. Best Pract Res Clin Endocrinol Metab 2007; 21:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/3\">",
"      Liu YY, Brent GA. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends Endocrinol Metab 2010; 21:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/4\">",
"      Davis PJ, Davis FB, Cody V. Membrane receptors mediating thyroid hormone action. Trends Endocrinol Metab 2005; 16:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/5\">",
"      Jansen J, Friesema EC, Milici C, Visser TJ. Thyroid hormone transporters in health and disease. Thyroid 2005; 15:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/6\">",
"      Heuer H, Visser TJ. Minireview: Pathophysiological importance of thyroid hormone transporters. Endocrinology 2009; 150:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/7\">",
"      Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002; 23:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/8\">",
"      Gereben B, Zavacki AM, Ribich S, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 2008; 29:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/9\">",
"      Maia AL, Kim BW, Huang SA, et al. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 2005; 115:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/10\">",
"      Schulman, AI, Mangelsdorf, DJ. Retinoid X Receptors in the metabolic syndrome N Engl J Med 2005; 353:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/11\">",
"      Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. J Neuroendocrinol 2008; 20:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/12\">",
"      Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007; 92:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/13\">",
"      Brent GA. Tissue-specific actions of thyroid hormone: insights from animal models. Rev Endocr Metab Disord 2000; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/14\">",
"      Cheng SY. Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. Trends Endocrinol Metab 2005; 16:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/15\">",
"      Vennstr&ouml;m B, Mittag J, Wallis K. Severe psychomotor and metabolic damages caused by a mutant thyroid hormone receptor alpha 1 in mice: can patients with a similar mutation be found and treated? Acta Paediatr 2008; 97:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/16\">",
"      Liu YY, Schultz JJ, Brent GA. A thyroid hormone receptor alpha gene mutation (P398H) is associated with visceral adiposity and impaired catecholamine-stimulated lipolysis in mice. J Biol Chem 2003; 278:38913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/17\">",
"      G&ouml;the S, Wang Z, Ng L, et al. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev 1999; 13:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/18\">",
"      Weiss RE, Xu J, Ning G, et al. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 1999; 18:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/19\">",
"      Reutrakul S, Sadow PM, Pannain S, et al. Search for abnormalities of nuclear corepressors, coactivators, and a coregulator in families with resistance to thyroid hormone without mutations in thyroid hormone receptor beta or alpha genes. J Clin Endocrinol Metab 2000; 85:3609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/20\">",
"      Hernandez A, Martinez ME, Fiering S, et al. Type 3 deiodinase is critical for the maturation and function of the thyroid axis. J Clin Invest 2006; 116:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/21\">",
"      Weiss RE, Refetoff S. Effect of thyroid hormone on growth. Lessons from the syndrome of resistance to thyroid hormone. Endocrinol Metab Clin North Am 1996; 25:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/22\">",
"      Murphy E, Williams GR. The thyroid and the skeleton. Clin Endocrinol (Oxf) 2004; 61:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/23\">",
"      Bassett JH, Williams GR. Critical role of the hypothalamic-pituitary-thyroid axis in bone. Bone 2008; 43:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/24\">",
"      Mitchell CS, Savage DB, Dufour S, et al. Resistance to thyroid hormone is associated with raised energy expenditure, muscle mitochondrial uncoupling, and hyperphagia. J Clin Invest 2010; 120:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/25\">",
"      Brenta G, Danzi S, Klein I. Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 2007; 3:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/26\">",
"      Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005; 26:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/27\">",
"      Fox CS, Pencina MJ, D'Agostino RB, et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med 2008; 168:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/28\">",
"      Ortega E, Pannacciulli N, Bogardus C, Krakoff J. Plasma concentrations of free triiodothyronine predict weight change in euthyroid persons. Am J Clin Nutr 2007; 85:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/29\">",
"      Haluzik M, Nedvidkova J, Bartak V, et al. Effects of hypo- and hyperthyroidism on noradrenergic activity and glycerol concentrations in human subcutaneous abdominal adipose tissue assessed with microdialysis. J Clin Endocrinol Metab 2003; 88:5605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/30\">",
"      Chidakel A, Mentuccia D, Celi FS. Peripheral metabolism of thyroid hormone and glucose homeostasis. Thyroid 2005; 15:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/31\">",
"      Crunkhorn S, Patti ME. Links between thyroid hormone action, oxidative metabolism, and diabetes risk? Thyroid 2008; 18:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/32\">",
"      Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med 1995; 333:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/33\">",
"      Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/34\">",
"      M&uuml;ller B, Zulewski H, Huber P, et al. Impaired action of thyroid hormone associated with smoking in women with hypothyroidism. N Engl J Med 1995; 333:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/35\">",
"      Brucker-Davis F. Effects of environmental synthetic chemicals on thyroid function. Thyroid 1998; 8:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/36\">",
"      Doh&aacute;n O, De la Vieja A, Paroder V, et al. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003; 24:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/37\">",
"      Hershman JM. Perchlorate and thyroid function: what are the environmental issues? Thyroid 2005; 15:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/38\">",
"      Messina M, Redmond G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. Thyroid 2006; 16:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/39\">",
"      Cable EE, Finn PD, Stebbins JW, et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009; 49:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/40\">",
"      Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/41\">",
"      Safer JD, Crawford TM, Holick MF. Topical thyroid hormone accelerates wound healing in mice. Endocrinology 2005; 146:4425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/42\">",
"      Sherman SI, Ringel MD, Smith MJ, et al. Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. J Clin Endocrinol Metab 1997; 82:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/43\">",
"      Freitas FR, Moriscot AS, Jorgetti V, et al. Spared bone mass in rats treated with thyroid hormone receptor TR beta-selective compound GC-1. Am J Physiol Endocrinol Metab 2003; 285:E1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/44\">",
"      Grover GJ, Mellstr&ouml;m K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 2003; 100:10067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/45\">",
"      Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/46\">",
"      Sabatino L, Colantuoni A, Iervasi G. Is the vascular system a main target for thyroid hormones? From molecular and biochemical findings to clinical perspectives. Curr Vasc Pharmacol 2005; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10200/abstract/47\">",
"      Goldman S, McCarren M, Morkin E, et al. DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 2009; 119:3093.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7864 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10200=[""].join("\n");
var outline_f9_61_10200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16987421\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF T3 ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ligand availability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thyroid hormone nuclear receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Receptor cofactors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DNA regulatory elements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THYROID HORMONE ACTIONS DURING DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ligand availability during fetal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Expression pattern of TR isoforms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TISSUE-SPECIFIC THYROID HORMONE ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tissue-specific expression of TR isoforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TR cofactors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DNA response elements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tissue-specific expression of thyroid hormone deiodinases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      THYROID HORMONE ACTION IN BONE, HEART, AND REGULATION OF METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bone and bone development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiac gene expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Regulation of metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      AGENTS THAT MAY INTERFERE WITH THYROID HORMONE ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical markers of thyroid hormone action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Selective thyroid hormone analogs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16987421\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7864\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7864|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/40/9870\" title=\"figure 1A\">",
"      Thyroid hormone action part A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/33/21022\" title=\"figure 1B\">",
"      Thyroid hormone action part B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/4/36928\" title=\"figure 2\">",
"      T3 nuclear receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/50/5935\" title=\"figure 3\">",
"      TR isoform tissue distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7864|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/41/22172\" title=\"table 1\">",
"      TR knockout phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/35/13883\" title=\"table 2\">",
"      Thyroid hormone receptor isoform-specific actions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16518?source=related_link\">",
"      Resistance to thyrotropin and thyrotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40696?source=related_link\">",
"      Thyroid physiology and screening in preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_61_10201="Emergent evaluation of acute upper airway obstruction in children";
var content_f9_61_10201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergent evaluation of acute upper airway obstruction in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10201/contributors\">",
"     Laura L Loftis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10201/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10201/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10201/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10201/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/61/10201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute upper airway obstruction from any cause can be a life-threatening emergency. Complete obstruction will result in respiratory failure followed by cardiac arrest in a matter of minutes. This situation requires an immediate, aggressive response.",
"   </p>",
"   <p>",
"    In contrast, a child with a partial obstruction may initially have an adequate airway. However, this condition can deteriorate rapidly. Under these circumstances, providing supportive care and mobilizing resources for definitive airway management may be the most appropriate intervention.",
"   </p>",
"   <p>",
"    Compared with adults, infants and young children have small airways and can quickly develop clinically significant upper airway obstruction. The increased work of breathing that results can rapidly progress to respiratory failure because these young patients have less respiratory reserve. Therefore, prompt recognition of airway compromise and the institution of appropriate therapy are necessary to prevent progressive deterioration in respiratory function and improve outcomes.",
"   </p>",
"   <p>",
"    This topic will review an emergent diagnostic and therapeutic approach to acute severe upper airway obstruction in children. The emergent evaluation of children with acute respiratory distress and issues related to stridor, chronic upper airway problems, and airway management techniques for the difficult pediatric airway are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=see_link\">",
"       \"Emergent evaluation of acute respiratory compromise in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"       \"Assessment of stridor in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4102?source=see_link\">",
"       \"Evaluation of the child with hoarseness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"       \"The difficult pediatric airway\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39337?source=see_link\">",
"       \"Devices for difficult endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37593?source=see_link\">",
"       \"Emergency rescue devices for difficult pediatric airway management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any condition that causes upper airway obstruction can be life-threatening (",
"    <a class=\"graphic graphic_table graphicRef62015 \" href=\"UTD.htm?2/44/2763\">",
"     table 1",
"    </a>",
"    ). However, most children have an identifiable etiology and respond well with prompt recognition and appropriate intervention. The most common cause of upper airway obstruction in children is croup&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Croup'",
"    </a>",
"    below.) Choking on a foreign body also occurs frequently, resulting in 17,000 emergency department visits for children less than 14 years of age in 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discussion here will emphasize causes that can result in severe, rapidly progressive symptoms. The causes of mild upper airway obstruction and the assessment of stridor are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"     \"Assessment of stridor in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Decreased muscle tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tongue can fall back into the pharynx and obstruct the airway in children with decreased oropharyngeal muscle tone, as can occur with depressed levels of consciousness or neuromuscular disease. Simply repositioning the airway may relieve the obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infectious etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infectious processes that affect the upper airway cause a gradual onset of symptoms such as cough, change in voice, and difficulty swallowing. Infection directly involving structures of the upper airway, such as the epiglottis, larynx, or subglottic trachea, can cause sudden, life-threatening symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Epiglottitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epiglottitis (supraglottitis) is a life-threatening infection characterized by rapidly progressive inflammation of and around the epiglottis. Common symptoms of upper airway compromise include dysphagia, muffled voice, and difficulty handling oral secretions. The incidence of epiglottitis has declined dramatically since routine infant vaccination with Haemophilus influenzae type b (Hib) protein-polysaccharide conjugate vaccines began in 1991. A detailed discussion of epiglottitis is found elsewhere (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67878 \" href=\"UTD.htm?22/26/22958\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Croup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngitis, laryngotracheitis, and laryngotracheobronchitis are synonyms for a viral infection involving the larynx and trachea. Spasmodic croup causes symptoms that are the same as those of laryngotracheitis, but without fever. There may be an allergic component to spasmodic croup.",
"   </p>",
"   <p>",
"    All of these processes cause inflammation of the subglottic trachea that results in cough, hoarseness, stridor, and respiratory distress. The severity of the distress depends upon the degree of obstruction. Croup, frequently a mild illness, is the most common infectious cause of upper airway obstruction in children 6 to 36 months of age. It is discussed in detail elsewhere (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52418 \" href=\"UTD.htm?2/56/2959\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64727 \" href=\"UTD.htm?41/59/42943\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"UTD.htm?33/50/34606\">",
"     image 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31144?source=see_link\">",
"     \"Approach to the management of croup\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Bacterial tracheitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial tracheitis may be a complication of viral laryngotracheitis or a primary bacterial infection. Children are generally older than those with croup, have more severe symptoms, and are highly febrile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=see_link\">",
"     \"Bacterial tracheitis in children: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Retropharyngeal abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retropharyngeal abscess may extrinsically compress structures in the upper airway. Prominent presenting complaints are usually neck pain, fever, and sore throat rather than acute, severe airway obstruction. A detailed discussion of retropharyngeal abscess may be found separately (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63233 \" href=\"UTD.htm?23/20/23887\">",
"     image 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Peritonsillar abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonsillar abscess generally occurs in later childhood and adolescence. The sudden onset of severe respiratory distress is rare. Peritonsillar abscess is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Infectious mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction of the upper airway due to massive tonsillar enlargement and mucosal edema is an uncommon and potentially fatal complication of infectious mononucleosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Foreign bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small children often choke on food or small objects and usually clear the obstruction spontaneously with coughing and choking. In a retrospective report, the majority of prehospital calls for airway obstruction in children less than five years of age were caused by a foreign object [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/4\">",
"     4",
"    </a>",
"    ]. Symptoms resolved in more than half of children prior to the arrival of paramedics. An intervention was required in 2 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Airway foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most aspirated objects lodge in the bronchi and are not immediately life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/5\">",
"     5",
"    </a>",
"    ]. Although rare, foreign bodies in the larynx or trachea can cause significant complete or partial airway obstruction that requires immediate treatment. An approach to upper airway foreign bodies is discussed below. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Algorithmic approach'",
"    </a>",
"    below.) The presentation, evaluation, and management of lower airway foreign bodies are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Esophageal foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign bodies lodged in the esophagus in the area of the cricoid cartilage or the tracheal bifurcation can compress the airway causing partial airway obstruction. It is also possible that an esophageal foreign body will become dislodged into the upper airway. The presentation, evaluation, and management of esophageal foreign bodies is discussed in detail elsewhere (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76887 \" href=\"UTD.htm?14/15/14578\">",
"     image 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Blunt and penetrating injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt or penetrating injury to various anatomic structures may result in upper airway obstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traumatic injury to the face may cause soft tissue swelling or hemorrhage, leading to airway compromise.",
"     </li>",
"     <li>",
"      Blunt or penetrating trauma to the larynx or subglottic trachea may result in dyspnea, altered phonation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      subcutaneous emphysema [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Injury to the epiglottis can cause swelling and upper airway obstruction with a clinical presentation indistinguishable from infectious epiglottitis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Burn injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of facial burns or singed facial hairs should alert the practitioner to the possibility of thermal injuries to the upper airway. Although there may be no initial airway compromise, edema can rapidly progress.",
"   </p>",
"   <p>",
"    Thermal injury to the epiglottitis, usually from hot beverages, has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/7\">",
"     7",
"    </a>",
"    ]. Thermal injury below the vocal cords is unlikely due to the cooling efficiency of the upper airways [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis and anaphylactoid reactions may be severe and life-threatening when edema involves the retropharynx",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    larynx. Onset of symptoms is usually sudden, and there may be associated signs such as urticaria and facial swelling. Emergent treatment can be life-saving (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Severe upper airway obstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hereditary angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal edema occurs in approximately one-half of all patients with hereditary angioedema at some point during their lifetime. Tooth extraction and oral surgery are common triggers for laryngeal attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vocal cord dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngospasm is an acute manifestation of vocal cord dysfunction that is usually precipitated by irritation of the vocal cords, as can occur with aspiration. Hypocalcemic tetany is a rare cause of laryngospasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of hypocalcemia\", section on 'Tetany'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The symptoms of vocal cord dysfunction (VCD) are usually chronic. The acute onset or worsening of stridor from VCD can be alarming and may be a clue to a more serious and possibly progressive problem. This is particularly true when the VCD is due to a lesion in the brainstem. As an example, vocal cord dysfunction can occur in children with Chiari II malformations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\", section on 'Chiari II malformation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anatomy and physiology of vocal cord function are discussed extensively elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4102?source=see_link\">",
"     \"Evaluation of the child with hoarseness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involuntary vocal cord adduction during inspiration has been described in children and adolescents. Severe symptoms of upper airway obstruction may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"     \"Paradoxical vocal cord motion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acute on chronic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have chronic narrowing of the upper airway from any cause can develop critical obstruction with an acute illness or injury that affects the upper airway (",
"    <a class=\"graphic graphic_table graphicRef62718 graphicRef71405 \" href=\"UTD.htm?5/6/5230\">",
"     table 3A-B",
"    </a>",
"    ). As an example, a child with mild stridor as the result of a laryngeal web may develop severe obstruction with an URI. Similarly, mild upper airway obstruction as the result of extrinsic compression of the trachea from a neoplasm can become acutely life-threatening if bleeding into the tumor causes it to suddenly expand.",
"   </p>",
"   <p>",
"    Most children with chronic causes of upper airway obstruction become symptomatic gradually, usually in early infancy. Some conditions, such as lymphatic malformations, may become evident at an older age, in association with infection or, occasionally, trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/9\">",
"     9",
"    </a>",
"    ]. Congenital anomalies affecting the airway are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=see_link\">",
"     \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=see_link\">",
"     \"Congenital anomalies of the larynx\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Initial rapid assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of children with signs and symptoms of acute upper airway obstruction must begin with a rapid assessment of respiratory status to identify those who need resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/10\">",
"     10",
"    </a>",
"    ]. Conditions that require immediate intervention include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete upper airway obstruction",
"     </li>",
"     <li>",
"      Rapidly progressing partial airway obstruction",
"     </li>",
"     <li>",
"      Respiratory failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To rapidly identify the presence of these conditions, the clinician should focus upon signs of upper airway patency, the degree of respiratory effort, and the effectiveness of respiratory function. Throughout this evaluation, every reasonable effort must be made to keep the child calm and comfortable, since anxiety and crying can substantially increase airway obstruction and the work of breathing in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Upper airway patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no effective air movement in children with complete upper airway obstruction. Consequently, there is no audible speech or cough, although the child may be gagging or choking in an attempt to clear the airway.",
"   </p>",
"   <p>",
"    Audible phonation or breath sounds indicates that the airway is patent, although it may be partially obstructed. With partial extrathoracic upper airway obstruction, respirations are usually noisy in inspiration (stridor).",
"   </p>",
"   <p>",
"    A child with worsening obstruction may have an airway that is patent but inadequate because complete obstruction is imminent. Worsening respiratory distress (retractions, nasal flaring) with diminished air movement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    worsening hypoxemia (poor color and decreased mental status) suggest that the obstruction is rapidly progressive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with respiratory failure have developed inadequate oxygenation, inadequate ventilation, or both. The following clinical features indicate respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor color (ashen or centrally cyanotic)",
"     </li>",
"     <li>",
"      Obtunded mental status",
"     </li>",
"     <li>",
"      Decreased chest wall movement, with or without signs of respiratory distress",
"     </li>",
"     <li>",
"      Bradypnea or marked tachypnea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As respiratory failure progresses, the child's respiratory rate often decreases and the pattern of respirations becomes irregular. Without intervention, respiratory arrest quickly develops.",
"   </p>",
"   <p>",
"    It is often impractical to initially measure pulse oximetry in an anxious child with respiratory distress. Poor color and decreased mental status are indications of hypoxemia in this situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two historical variables that are particularly helpful in determining initial management priorities are onset of symptoms and presence of fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Onset of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sudden onset of choking, gagging, or stridor suggests a foreign body or an allergic reaction. In general, symptoms that have been rapidly progressive indicate severe disease. By comparison, the gradual development of hoarseness then worsening to stridor suggests less severe involvement, as in viral croup.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of fever suggests an infectious etiology. Rapid onset of symptoms in a febrile child is more likely in a bacterial process such as epiglottitis, bacterial tracheitis, retropharyngeal abscess, or peritonsillar abscess.",
"   </p>",
"   <p>",
"    Other useful historical information includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Change in voice",
"      </strong>",
"      &ndash; Most children with acute upper airway pathology will have a change in voice. A muffled voice can be seen in supraglottic processes such as infection (epiglottitis or peritonsillar abscess) or injury. Hoarseness or stridor occurs with laryngeal or subglottic inflammation, as with croup.",
"     </li>",
"     <li>",
"      <strong>",
"       Exposures",
"      </strong>",
"      &ndash; An allergic reaction may be the cause of upper airway obstruction when symptoms are related to exposure to a known allergen or new food or medication. Smoke inhalation can result in chemical or thermal injury to the airway.",
"     </li>",
"     <li>",
"      <strong>",
"       Underlying medical conditions",
"      </strong>",
"      &ndash; More severe symptoms are frequently observed in children with congenital anomalies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      previous airway surgery who develop inflammation of the upper airway from any cause. Similarly, children with underlying poor tone or neuromuscular disease (Down syndrome, cerebral palsy, muscular dystrophy, quadriplegia) are at increased risk of more severe symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the child with severe respiratory distress, the initial physical examination may consist solely of a rapid respiratory assessment. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Initial rapid assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Vital signs, including weight, should be obtained as the child's respiratory status permits. A careful examination of the pharynx and lungs can be performed as soon as the child's condition is stabilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Signs of airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the signs of airway obstruction previously mentioned (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Upper airway patency'",
"    </a>",
"    above), upper airway obstruction is also indicated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with significant obstruction may prefer to sit up and lean forward in a \"sniffing\" position (neck is mildly flexed and head is mildly extended). This position tends to improve the patency of the upper airway.",
"     </li>",
"     <li>",
"      There can be some degree of drooling when the patient is unable to swallow.",
"     </li>",
"     <li>",
"      Retractions (suprasternal and supraclavicular) and nasal flaring may be noted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Associated findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings may suggest a particular diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High fever, toxic appearance, and moderate respiratory distress in a school age child suggest bacterial tracheitis or, rarely, epiglottitis.",
"     </li>",
"     <li>",
"      Signs such as choking, gagging, or difficulty swallowing are more sensitive for the presence of upper airway foreign body than inspection of the posterior pharynx.",
"     </li>",
"     <li>",
"      The acute onset of upper airway symptoms with facial swelling and wheezing are consistent with an allergic reaction.",
"     </li>",
"     <li>",
"      Bleeding, bruising, or subcutaneous air suggest blunt or penetrating trauma.",
"     </li>",
"     <li>",
"      The child with burns or singed hair who has hoarseness or respiratory distress may have a burn injury to the upper airway.",
"     </li>",
"     <li>",
"      An infant or toddler who is irritable, not moving the neck, and who will not swallow may have a retropharyngeal abscess.",
"     </li>",
"     <li>",
"      Peritonsillar abscess can present in the older child as a muffled (eg, hot potato) voice and trismus. Palatal cellulitis and a bulging mass are apparent on examination of the pharynx.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation must proceed in conjunction with treatment. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Algorithmic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging may be useful in identifying the location and nature of the airway obstruction but should never interfere with the stabilization of a child with a critical obstruction. Soft tissue radiographs of the neck can be helpful in diagnosing epiglottitis and croup (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67878 \" href=\"UTD.htm?22/26/22958\">",
"     image 1",
"    </a>",
"    ). AP and lateral neck and chest films may demonstrate the presence of a foreign body, but many foreign bodies are radiolucent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of the laboratory in establishing the diagnosis is limited. In the child with a bacteriologic etiology such as epiglottitis or a retropharyngeal abscess, a throat culture or blood culture may provide important information for ongoing antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Direct laryngoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngoscopy for diagnostic purposes alone is rarely necessary in children with acute upper airway obstruction. It is the diagnostic method of choice for vocal cord dysfunction during an acute episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     ALGORITHMIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child who has a complete airway obstruction must be identified immediately and life-saving maneuvers initiated. Although the etiology of the obstruction must be considered, the response to therapeutic interventions directs initial management (",
"    <a class=\"graphic graphic_algorithm graphicRef55990 \" href=\"UTD.htm?22/48/23296\">",
"     algorithm 1A",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strategy is somewhat different in the child with severe but partial upper airway obstruction. In this setting, clinical features suggest the diagnosis and guide therapeutic interventions (",
"    <a class=\"graphic graphic_algorithm graphicRef54996 \" href=\"UTD.htm?9/37/9810\">",
"     algorithm 1B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     No airway, complete obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;With complete upper airway obstruction, there is no effective air movement. Initially, the child is anxious, struggling to breathe, and may be silently gagging or coughing in an attempt to clear the airway. The child's condition will rapidly deteriorate, with loss of consciousness, if the obstruction is not relieved. Treatment must be initiated immediately. The most expert physician available, who may be from anesthesia or otorhinolaryngology rather than emergency medicine or pediatrics, should manage the airway (",
"    <a class=\"graphic graphic_algorithm graphicRef55990 \" href=\"UTD.htm?22/48/23296\">",
"     algorithm 1A",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Suspected foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden onset of symptoms in a previously well child suggests the possibility that a foreign body may be obstructing the airway. Basic life saving (BLS) maneuvers for foreign body airway obstruction should be initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in cadavers have demonstrated that chest compressions and abdominal thrusts are each effective in generating sufficient pressure to expel a supraglottic foreign body [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/14\">",
"     14",
"    </a>",
"    ]. Based upon this limited evidence and extensive clinical experience, the American Heart Association recommends chest compressions or abdominal thrusts as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants less than one year of age, five back blows are delivered, followed by five chest thrusts. Abdominal thrusts are not recommended for infants less than one year of age because they may cause damage to the liver, which is relatively large and unprotected in this age group.",
"     </li>",
"     <li>",
"      For children one year of age or older, five abdominal thrusts (Heimlich maneuver) should be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the obstruction is relieved and the child resumes breathing adequately, he or she should at least be observed to confirm the diagnosis of relieved foreign body airway obstruction and that recovery has been complete.",
"   </p>",
"   <p>",
"    Direct laryngoscopy should be performed when complete upper airway obstruction has not been relieved with BLS maneuvers. In some cases, foreign material can be removed with Magill forceps",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suction. The child who begins to breathe adequately should receive supportive care, including supplemental oxygen, and be admitted to the hospital for observation. Bag-mask ventilation should be provided to patients who do not resume breathing spontaneously. Those who can be adequately ventilated and oxygenated should receive ongoing airway support and may require endotracheal intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39337?source=see_link\">",
"     \"Devices for difficult endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete airway obstruction that is unremovable with direct laryngoscopy may occur with a foreign body that is lodged above or below the vocal cords:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a foreign body causing complete airway obstruction above the vocal cords cannot be removed, we recommend needle cricothyroidotomy with percutaneous transtracheal jet ventilation to bypass the obstruction, providing oxygenation. Case reports and studies in dogs have documented adequate oxygenation, despite poor ventilation, using this technique [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Patients should then be immediately transferred to the operating room for definitive removal of the obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=see_link\">",
"       \"Needle cricothyroidotomy with percutaneous transtracheal ventilation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A foreign body that is lodged below the vocal cords may completely obstruct the subglottic trachea. This obstruction cannot be removed with direct laryngoscopy. In this situation, we recommend that the trachea be intubated and the endotracheal tube advanced into the right mainstem bronchus. This maneuver is an attempt to relieve the tracheal obstruction by pushing it into the right mainstem bronchus. At this point, the endotracheal tube should be withdrawn to a position above the carina. The left lung can then be ventilated. The child will now have a bronchial foreign body, but may receive adequate ventilation and oxygenation while preparations are being made to remove it in the operating room. There is no evidence to support the effectiveness of this approach in the setting of complete subglottic airway obstruction from a foreign body. However, case reports of patients requiring one lung ventilation for surgical procedures and studies in dogs have demonstrated effective oxygenation and ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     No foreign body suspected",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete upper airway obstruction may develop as the result of many processes other than a foreign body. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Causes'",
"    </a>",
"    above.) When this occurs, bag-mask ventilation should be initiated (",
"    <a class=\"graphic graphic_algorithm graphicRef58510 \" href=\"UTD.htm?21/54/22382\">",
"     algorithm 1C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    .) If this results in successful ventilation and oxygenation, preparations can be made for controlled intubation. Evaluation and treatment of the condition causing airway obstruction can also be initiated.",
"   </p>",
"   <p>",
"    When bag-mask ventilation is not rapidly successful, endotracheal intubation should be performed (",
"    <a class=\"graphic graphic_algorithm graphicRef58510 \" href=\"UTD.htm?21/54/22382\">",
"     algorithm 1C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"     table 4",
"    </a>",
"    ). If this is accomplished and ventilation and oxygenation are adequate, medical management of the underlying condition can continue. Admission to a pediatric intensive care unit should be arranged.",
"   </p>",
"   <p>",
"    When endotracheal intubation cannot be performed, use of a laryngeal mask airway (LMA) should be considered (",
"    <a class=\"graphic graphic_algorithm graphicRef73112 \" href=\"UTD.htm?12/9/12446\">",
"     algorithm 1D",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67558 \" href=\"UTD.htm?4/6/4203\">",
"     table 5",
"    </a>",
"    ). Although evidence suggesting efficacy in children is lacking, successful oxygenation and ventilation with an LMA have been described in adults with upper airway obstruction from supraglottic edema [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37593?source=see_link&amp;anchor=H8354652#H8354652\">",
"     \"Emergency rescue devices for difficult pediatric airway management\", section on 'Laryngeal mask airway (LMA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Needle cricothyroidotomy and transtracheal jet ventilation may also bypass the obstruction and provide some ventilation and oxygenation while preparations are being made to take the child to the operating room (",
"    <a class=\"graphic graphic_figure graphicRef73518 \" href=\"UTD.htm?14/22/14696\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70963 \" href=\"UTD.htm?16/56/17288\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63745 \" href=\"UTD.htm?7/33/7709\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=see_link\">",
"     \"Needle cricothyroidotomy with percutaneous transtracheal ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Severe upper airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early, appropriate treatment of many causes of upper airway obstruction frequently stabilizes the child's respiratory function and prevents decompensation. However, it is important to realize that aggressive airway intervention in some clinical settings may result in dramatic deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/11\">",
"     11",
"    </a>",
"    ]. Therefore, the initial approach to the child with severe symptoms includes a rapid assessment of respiratory function and identification of key clinical features (such as history of injury, fever, and onset of symptoms) that suggest the diagnosis and guide therapeutic interventions (",
"    <a class=\"graphic graphic_algorithm graphicRef54996 \" href=\"UTD.htm?9/37/9810\">",
"     algorithm 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Imminent decompensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with burns around the face, a caustic ingestion, or another injury that has resulted in airway symptoms may suddenly develop worsening airway swelling and obstruction. Children without an injury who are deteriorating rapidly also require a secure airway. In both of these situations, patients require emergent controlled intubation. Consideration should be given to mobilizing subspecialty support, including anesthesia or otorhinolaryngology (",
"    <a class=\"graphic graphic_algorithm graphicRef58510 \" href=\"UTD.htm?21/54/22382\">",
"     algorithm 1C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H25#H25\">",
"     \"The difficult pediatric airway\", section on 'Airway management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fever suggests an infectious cause of upper airway obstruction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Croup/tracheitis",
"       </strong>",
"      </span>",
"      &ndash; The gradual onset of hoarseness and cough, with other upper respiratory tract symptoms is consistent with croup or tracheitis. As with all children who have severe upper airway obstruction, the patient must be approached cautiously. The caregiver should be instructed to comfort the child and administer humidified oxygen, whenever possible. Nebulized epinephrine should be quickly added. Also, children with croup require treatment with corticosteroids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31144?source=see_link\">",
"       \"Approach to the management of croup\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients who have responded to nebulized epinephrine must be observed for three to four hours. Those with croup who continue to do well may be discharged with close follow-up. Children with tracheitis are usually more toxic and should be admitted to the hospital. In retrospective reports describing hospitalized children with severe upper airway infections, more children with bacterial tracheitis required admission to intensive care units and intubation than did those with viral croup [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10201/abstract/20-22\">",
"       20-22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Epiglottitis, retropharyngeal, or peritonsillar abscess",
"      </strong>",
"      &ndash; Children who rapidly develop high fever, a toxic appearance, and severe upper airway obstruction may have a bacterial illness such as epiglottitis. Patients often have a muffled voice and difficulty swallowing.",
"      <br/>",
"      <br/>",
"      Symptoms of a retropharyngeal abscess include fever, neck pain, and sore throat. They may not progress as quickly as those of epiglottitis.",
"      <br/>",
"      <br/>",
"      Older children with a peritonsillar abscess may rarely have symptoms of severe upper airway obstruction. On examination, palatal cellulitis, with a bulging mass, is noted.",
"      <br/>",
"      <br/>",
"      Patients with epiglottitis, retropharyngeal, or peritonsillar abscesses should receive appropriate antibiotics. Those with retropharyngeal abscesses may require radiographic evaluation to define the extent of infection. Consultation with an otorhinolaryngologist and hospital admission are also indicated for patients with severe upper airway obstruction secondary to retropharyngeal abscesses. Emergent incision and drainage of a peritonsillar abscess by the emergency physician or an otorhinolaryngologist, followed by hospital admission, is recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"       \"Peritonsillar cellulitis and abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Indications for definitive airway management",
"      </strong>",
"      &ndash; Children with epiglottitis and those with other infectious etiologies whose condition is deteriorating require immediate airway management by the most skilled physician available. Time permitting, emergent subspecialty (otorhinolaryngology and anesthesia) consultation should be obtained and the patient taken to the operating room for definitive airway management. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"       \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     No fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of severe upper airway obstruction that develop suddenly in children without fever may be the result of trauma, a foreign body lodged in the upper airway, or acute swelling of the airway secondary to anaphylaxis or spasmodic croup.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Trauma, foreign body",
"      </strong>",
"      &ndash; A history of trauma or choking on a foreign body requires evaluation for a laryngotracheal injury or removal of a subglottic foreign body. Emergent subspecialty consultation should be obtained, with definitive management in the operating room whenever possible.",
"     </li>",
"     <li>",
"      <strong>",
"       Anaphylaxis",
"      </strong>",
"      &ndash; The sudden onset of symptoms without associated trauma or choking in a child with urticaria, facial swelling, or wheezing suggests anaphylaxis. In this situation, patients should immediately receive intramuscular epinephrine, followed promptly by",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      intramuscularly or intravenously. The addition of corticosteroids should be considered (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 2",
"      </a>",
"      ). Patients who have had severe upper airway obstruction secondary to an allergic reaction should be admitted to the hospital for observation.",
"     </li>",
"     <li>",
"      <strong>",
"       Spasmodic croup",
"      </strong>",
"      &ndash; Children with the sudden onset of acute upper airway obstruction without associated allergic symptoms may have spasmodic croup. Treatment with nebulized epinephrine and steroids should be initiated. Those who respond to these interventions must be observed for three to four hours and admitted if symptoms recur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31144?source=see_link\">",
"       \"Approach to the management of croup\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Indications for definitive airway management",
"      </strong>",
"      &ndash; Children with a laryngeal injury or upper airway foreign body require emergent subspecialty consultation, with definitive management in the operating room whenever possible. Those with anaphylaxis or spasmodic croup generally improve with medical therapy. However, prompt definitive airway management, which may include intubation, is required for those with persistent or worsening severe upper airway obstruction.",
"      <br/>",
"      <br/>",
"      Infants with the gradual onset of severe upper airway obstruction may have laryngomalacia (also called congenital laryngeal stridor) or another congenital anomaly. Admission to the hospital for further evaluation and supportive care should be considered. Older children may have a neoplasm or tonsillar hypertrophy. Symptoms of severe upper airway obstruction can only be attributed to psychogenic causes after a thorough evaluation and period of observation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=see_link&amp;anchor=H3#H3\">",
"       \"Congenital anomalies of the larynx\", section on 'Laryngomalacia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute upper airway obstruction can be a life-threatening emergency. There are many causes, including infections, aspirated foreign body, trauma, allergic reactions, and congenital anomalies (",
"      <a class=\"graphic graphic_table graphicRef62718 \" href=\"UTD.htm?2/12/2253\">",
"       table 3A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71405 \" href=\"UTD.htm?37/49/38684\">",
"       table 3B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt recognition of the child who requires resuscitation and therapeutic intervention is essential (",
"      <a class=\"graphic graphic_table graphicRef62015 \" href=\"UTD.htm?2/44/2763\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Initial rapid assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that influence choice of treatment options include degree of airway compromise, presence of fever, sudden onset of symptoms, history of injury, and age. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The algorithms provide an approach to evaluation and treatment of the child with acute severe upper airway obstruction or complete airway obstruction and the approach to the management of the difficult or failed airway (",
"      <a class=\"graphic graphic_algorithm graphicRef55990 graphicRef54996 graphicRef58510 graphicRef73112 \" href=\"UTD.htm?28/51/29496\">",
"       algorithm 1A-D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'No airway, complete obstruction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H39\">",
"       'Severe upper airway obstruction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/1\">",
"      DeSoto, H. Epiglottitis and croup in airway obstruction in children. Anesthesiol Clin North Am 1998; 16:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Nonfatal choking-related episodes among children--United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/3\">",
"      Chan SC, Dawes PJ. The management of severe infectious mononucleosis tonsillitis and upper airway obstruction. J Laryngol Otol 2001; 115:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/4\">",
"      Vilke GM, Smith AM, Ray LU, et al. Airway obstruction in children aged less than 5 years: the prehospital experience. Prehosp Emerg Care 2004; 8:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/5\">",
"      Tan HK, Brown K, McGill T, et al. Airway foreign bodies (FB): a 10-year review. Int J Pediatr Otorhinolaryngol 2000; 56:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/6\">",
"      Dalal FY, Schmidt GB, Bennett EJ, Levitsky S. Fractures of the larynx in children. Can Anaesth Soc J 1974; 21:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/7\">",
"      Yen K, Flanary V, Estel C, et al. Traumatic epiglottitis. Pediatr Emerg Care 2003; 19:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/8\">",
"      Fein A, Leff A, Hopewell PC. Pathophysiology and management of the complications resulting from fire and the inhaled products of combustion: review of the literature. Crit Care Med 1980; 8:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/9\">",
"      Rahbar R, Rowley H, Perez-Atayde AR, et al. Delayed presentation of lymphatic malformation of the cervicofacial region: role of trauma. Ann Otol Rhinol Laryngol 2002; 111:828.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual. Ralston, M, et al (Eds), American Heart Association, Subcommittee on Pediatric Resuscitation, Dallas, 2006, p.41.",
"    </li>",
"    <li>",
"     Luten RC, Kisson N. The difficult pediatric airway. In: Manual of Emergency Airway Management, 2nd, Walls RM.  (Ed), Williams &amp; Wilkins, Philadelphia 2004. p.236.",
"    </li>",
"    <li>",
"     Perry H. Stridor. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.643.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/13\">",
"      ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/14\">",
"      Langhelle A, Sunde K, Wik L, Steen PA. Airway pressure with chest compressions versus Heimlich manoeuvre in recently dead adults with complete airway obstruction. Resuscitation 2000; 44:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/15\">",
"      Patel RG. Percutaneous transtracheal jet ventilation: a safe, quick, and temporary way to provide oxygenation and ventilation when conventional methods are unsuccessful. Chest 1999; 116:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/16\">",
"      Cot&eacute; CJ, Eavey RD, Todres ID, Jones DE. Cricothyroid membrane puncture: oxygenation and ventilation in a dog model using an intravenous catheter. Crit Care Med 1988; 16:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/17\">",
"      Pawar DK, Marraro GA. One lung ventilation in infants and children: experience with Marraro double lumen tube. Paediatr Anaesth 2005; 15:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/18\">",
"      Riquelme M, Monnet E, Kudnig ST, et al. Cardiopulmonary changes induced during one-lung ventilation in anesthetized dogs with a closed thoracic cavity. Am J Vet Res 2005; 66:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/19\">",
"      King CJ, Davey AJ, Chandradeva K. Emergency use of the laryngeal mask airway in severe upper airway obstruction caused by supraglottic oedema. Br J Anaesth 1995; 75:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/20\">",
"      Bernstein T, Brilli R, Jacobs B. Is bacterial tracheitis changing? A 14-month experience in a pediatric intensive care unit. Clin Infect Dis 1998; 27:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/21\">",
"      Hopkins A, Lahiri T, Salerno R, Heath B. Changing epidemiology of life-threatening upper airway infections: the reemergence of bacterial tracheitis. Pediatrics 2006; 118:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10201/abstract/22\">",
"      Sofer S, Dagan R, Tal A. The need for intubation in serious upper respiratory tract infection in pediatric patients (a retrospective study). Infection 1991; 19:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6455 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10201=[""].join("\n");
var outline_f9_61_10201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Decreased muscle tone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infectious etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Epiglottitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Croup",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Bacterial tracheitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Retropharyngeal abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Peritonsillar abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Infectious mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Airway foreign body",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Esophageal foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Blunt and penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Burn injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hereditary angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vocal cord dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acute on chronic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Initial rapid assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Upper airway patency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Onset of symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Signs of airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Associated findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Microbiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Direct laryngoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      ALGORITHMIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      No airway, complete obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Suspected foreign body",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - No foreign body suspected",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Severe upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Imminent decompensation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - No fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6455\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6455|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/48/23296\" title=\"algorithm 1A\">",
"      Complete airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/37/9810\" title=\"algorithm 1B\">",
"      Severe upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/54/22382\" title=\"algorithm 1C\">",
"      Difficult airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?12/9/12446\" title=\"algorithm 1D\">",
"      Failed airway algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6455|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/26/22958\" title=\"diagnostic image 1\">",
"      Epiglottitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/56/2959\" title=\"diagnostic image 2\">",
"      Steeple sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/59/42943\" title=\"diagnostic image 3\">",
"      Croup lateral neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/50/34606\" title=\"diagnostic image 4\">",
"      Bacterial tracheitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/20/23887\" title=\"diagnostic image 5\">",
"      Retropharyngeal abscess plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/15/14578\" title=\"diagnostic image 6\">",
"      Esophageal foreign body",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6455|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/22/14696\" title=\"figure 1\">",
"      Percutaneous transtracheal ventilation anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/56/17288\" title=\"figure 2\">",
"      Percutaneous transtracheal ventilation procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6455|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/44/2763\" title=\"table 1\">",
"      Common lifethreat UAO children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 2\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/12/2253\" title=\"table 3A\">",
"      Congenital anomalies associated with stridor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/49/38684\" title=\"table 3B\">",
"      Causes of stridor other than congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 4\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/6/4203\" title=\"table 5\">",
"      LMA size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/33/7709\" title=\"table 6\">",
"      Percutaneous transtracheal ventilation summary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31144?source=related_link\">",
"      Approach to the management of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32536?source=related_link\">",
"      Bacterial tracheitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=related_link\">",
"      Congenital anomalies of the larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39337?source=related_link\">",
"      Devices for difficult endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37593?source=related_link\">",
"      Emergency rescue devices for difficult pediatric airway management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4102?source=related_link\">",
"      Evaluation of the child with hoarseness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16441?source=related_link\">",
"      Needle cricothyroidotomy with percutaneous transtracheal ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_61_10202="Pyoderma gangrenosum: Treatment and prognosis";
var content_f9_61_10202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pyoderma gangrenosum: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10202/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10202/contributors\">",
"     Courtney Schadt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10202/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10202/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/61/10202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/61/10202/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/61/10202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1178493\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative skin disorder characterized histopathologically by the accumulation of neutrophils in the skin. The most common presentation of PG is the rapid development of one or more painful, purulent ulcer with undermined borders on sites of normal or traumatized skin.",
"   </p>",
"   <p>",
"    Although multiple local and systemic therapies have been utilized for PG, high quality efficacy studies are lacking for most interventions. Topical and systemic corticosteroids, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are among the most commonly utilized pharmacologic agents.",
"   </p>",
"   <p>",
"    The management and prognosis of PG will be reviewed here. The pathogenesis, clinical features, and diagnosis of PG are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=see_link\">",
"     \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178500\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The careful exclusion of other disorders that may cause cutaneous ulceration is an important first step in the management of lesions that appear consistent with PG. This is of particular importance since certain therapies utilized for PG can be ineffective or harmful in other diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=see_link&amp;anchor=H24503942#H24503942\">",
"     \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=see_link&amp;anchor=H4374004#H4374004\">",
"     \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of the paucity of data on interventions for PG, definitive guidelines for patient management are lacking. The approach to the treatment of PG is primarily guided by small uncontrolled studies and clinical experience. In general, patients are managed with a combination of topical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic therapies that suppress the inflammatory process and wound care measures that optimize the environment for wound healing. Although initial signs of improvement may be evident within days of the start of treatment, weeks to months are often required to achieve complete ulcer healing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with mild PG (few superficial ulcers or vegetative PG), the local administration of corticosteroids or a calcineurin inhibitor can be sufficient for treatment. In contrast, systemic therapy is typically necessary in patients with more extensive PG. Glucocorticoids are the most common systemic drugs prescribed since a rapid response is often observed, and the drugs are relatively low in cost and are easily administered. Systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is an alternative first-line treatment for patients who cannot tolerate systemic glucocorticoid therapy.",
"   </p>",
"   <p>",
"    A wide variety of other systemic immunomodulatory drugs can be utilized as alternative or adjunctive treatments for PG that fails to respond sufficiently to first-line therapies. Examples include biologic drugs, conventional immunosuppressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    has demonstrated efficacy for PG in a randomized trial, and its concomitant utility in Crohn&rsquo;s disease favors the use of this drug in patients with both diseases. In patients with mild PG that is resistant to local therapy, we often prescribe a trial of dapsone or minocycline, which are generally well-tolerated, prior to treatment with immunosuppressive therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"     3",
"    </a>",
"    ]. Intravenous immunoglobulin (IVIG) and alkylating agents are treatment options that are typically reserved for patients with severe, refractory disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PG frequently occurs in association with other medical disorders, most commonly inflammatory bowel disease, hematologic malignancy, and arthritis. Although the course of the disease does not always parallel PG, treatment of the associated disorder sometimes results in improvement in PG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=see_link&amp;anchor=H4373281#H4373281\">",
"     \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\", section on 'Associated disorders'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1178633\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment options for PG are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603390\">",
"    <span class=\"h1\">",
"     FIRST-LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the severity of PG influences the choice of initial therapy. Although local interventions successfully induce healing in some patients with mild disease, patients with more extensive PG require systemic therapy to arrest disease activity. Documentation of the size, number, and location of ulcers and serial clinical photographs are useful for following the response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178507\">",
"    <span class=\"h2\">",
"     Wound management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of wound care in PG is to create an optimal environment for wound healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1796381\">",
"    <span class=\"h3\">",
"     Local care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds should be cleansed gently with tepid sterile saline or a mild antiseptic prior to dressing changes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/2\">",
"     2",
"    </a>",
"    ]. Wound dressings that promote a moist wound environment and do not adhere to the wound base are preferred, as they may be beneficial for healing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H456664428#H456664428\">",
"     \"Basic principles of wound management\", section on 'Importance of moisture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The selection of a specific type of wound dressing depends on the nature of the wound and patient and clinician preferences. As an example, patients with wounds that are highly exudative may benefit from the use of more absorptive wound dressings, such as alginates to avoid tissue maceration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link&amp;anchor=H55268776#H55268776\">",
"     \"Basic principles of wound management\", section on 'Wound dressings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Pathergy",
"    </strong>",
"    (exacerbation of lesions at sites of trauma) can occur in PG. Thus, unnecessary traumatic insults to the wound, such as the use of wet to dry dressings and the application of caustic substances (eg, sliver nitrate) should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=see_link&amp;anchor=H24503928#H24503928\">",
"     \"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the area of ulceration or erosion, attention should also be paid to the surrounding skin. Use of a barrier cream or ointment, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    paste or petrolatum, may help to prevent skin breakdown at the wound edge [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Patients should be monitored for clinical signs of wound infection (eg, fever, warmth, swelling, malodor, lymphangitic streaks, increased drainage, or pain), and should be treated appropriately with antibiotics if infection occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"     3",
"    </a>",
"    ]. Hyperbaric oxygen has been reported to be of benefit for wound healing in a few patients with PG, but data are insufficient to recommend the routine use of this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1796199\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the potential for pathergy, the role of surgery for wound management in PG is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Surgical procedures are considered only in select cases, such as those in which accumulation of necrotic tissue presents a risk for infection or where vital tissues such as tendons or ligaments are exposed in the ulcer bed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Although multiple cases in which PG worsened following surgical intervention have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/1,9\">",
"     1,9",
"    </a>",
"    ], documentation of cases in which gentle debridement, skin flaps or grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/12-15\">",
"     12-15",
"    </a>",
"    ], and the application of bioengineered keratinocyte autografts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/16\">",
"     16",
"    </a>",
"    ] or allogenic cultured dermal substitutes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/17\">",
"     17",
"    </a>",
"    ] appeared to be beneficial in PG exists. To minimize the likelihood of pathergy, performance of surgical procedures should be limited to periods of good disease control, and patients should be concomitantly treated with systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178521\">",
"    <span class=\"h2\">",
"     Limited disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local interventions can be used as initial therapy in patients with mild, localized PG (eg, few superficial ulcers or vegetative PG). When effective, local treatment is preferred due to the relatively low risk of serious adverse effects. The most common interventions utilized are topically or intralesionally administered corticosteroids and calcineurin inhibitors. Local therapy should be delivered to the ulcer&rsquo;s inflamed periphery. &nbsp;",
"   </p>",
"   <p>",
"    No randomized trials of topical or intralesional therapies for PG have been performed, and additional studies are necessary to determine the best approach to local management. We typically utilize a superpotent topical corticosteroid (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05% ointment) as initial therapy. Improvement is usually evident within two to three weeks. In patients who fail to demonstrate improvement with a superpotent topical corticosteroid within this time period, we attempt treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1% ointment or systemic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178528\">",
"    <span class=\"h3\">",
"     Local corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although topical corticosteroids are frequently prescribed as primary and adjunctive therapies in PG, data on the efficacy of these agents are limited to a few retrospective studies and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. High potency or superpotent topical corticosteroids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate, are usually applied once or twice daily (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). In one open-label study in which 5 of 13 patients treated with clobetasol 0.05% ointment or lotion achieved complete healing, the average time to healing was 6.5 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some clinicians, including ourselves, avoid intralesional injections due to concern for the induction of pathergy, case reports have documented efficacy of intralesional corticosteroid therapy in PG [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/10,20-23\">",
"     10,20-23",
"    </a>",
"    ]. Concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    between 6 and 40",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    have been utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/24\">",
"     24",
"    </a>",
"    ]. The corticosteroid is injected circumferentially into the ulcer periphery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous atrophy is one of the most common adverse effects of topical and intralesional corticosteroid therapy. Adverse effects are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link&amp;anchor=H7#H7\">",
"     \"Intralesional injection\", section on 'Side effects, complications, and pitfalls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178535\">",
"    <span class=\"h3\">",
"     Local calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in concentrations of 0.03% to 0.3% has demonstrated efficacy for PG in multiple case reports, a few prospective case series, and an open label study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/18,25,26\">",
"     18,25,26",
"    </a>",
"    ]. In the open label study, a compounded formulation of 0.3% tacrolimus in a carmellose sodium paste appeared to be effective for peristomal PG; 7 of 11 patients treated with the tacrolimus formulation and 5 of 13 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05% lotion or ointment achieved complete healing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is commercially available as a 0.03% and 0.1% ointment. We typically instruct the patient to apply the 0.1% ointment once to twice daily. Improvement may be evident within the first few days to weeks of treatment. However, complete healing of an ulcer may take several weeks to a few months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Treatment is usually well-tolerated; occasionally, patients experience mild burning sensations at the site of application [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other calcineurin inhibitors may have benefit for PG, but fewer data are available on these agents. A case report documented improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    1% cream [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/29\">",
"     29",
"    </a>",
"    ]. Improvement with topical or intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been described in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/30-33\">",
"     30-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178542\">",
"    <span class=\"h2\">",
"     More extensive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with PG cannot be managed with local therapy alone. Systemic treatment is used as a first-line intervention in PG that is not limited to a few superficial ulcers or a solitary plaque of vegetative PG. Systemic agents are also appropriate for patients with mild PG that fails to improve with local therapy.",
"   </p>",
"   <p>",
"    The systemic therapies utilized in PG are immunosuppressive and immunomodulatory agents that calm the inflammatory process to allow for wound healing. Systemic glucocorticoids often induce a rapid response and are typically used as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"     3",
"    </a>",
"    ]. In patients who cannot tolerate or fail to respond to systemic glucocorticoids, treatment with systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can be attempted. Of note, topical or intralesional corticosteroids and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are often used as adjuncts to systemic therapy. (See",
"    <a class=\"local\" href=\"#H1178528\">",
"     'Local corticosteroids'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1178535\">",
"     'Local calcineurin inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180235\">",
"    <span class=\"h3\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no randomized trials have evaluated the efficacy of systemic glucocorticoids for PG, multiple case reports, case series, and our clinical experience support the use of this treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/10,34\">",
"     10,34",
"    </a>",
"    ]. We typically initiate treatment with 0.5 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent, with a maximum dose of 60 mg of prednisone per day. In very aggressive or painful disease, intravenous pulse corticosteroids (1 g",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    per day for one to five days) can be used as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to systemic glucocorticoids is usually rapid; stabilization of the disease is often evident within the first week [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/38\">",
"     38",
"    </a>",
"    ]. Pain also tends to improve soon after the initiation of treatment. However, since complete ulcer healing may take weeks to months, and long-term therapy with systemic glucocorticoids is associated with significant adverse effects, glucocorticoids are tapered as soon as is feasible. We typically begin to taper glucocorticoids once disease progression has stopped and clear signs of improvement are noted (reductions in pain, visible inflammation, and wound size).",
"   </p>",
"   <p>",
"    We aim to taper and discontinue glucocorticoids within 4 to 10 weeks and monitor patients closely for continued improvement. We usually add a glucocorticoid-sparing agent (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) to maintain improvement during and after tapering. Tapering glucocorticoids too rapidly may precipitate disease flares [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1180242\">",
"    <span class=\"h3\">",
"     Systemic cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is used as an alternative first-line agent in patients who cannot tolerate glucocorticoid therapy and as an adjunctive or alternative therapy for patients who fail to respond adequately to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/10\">",
"     10",
"    </a>",
"    ]. Several retrospective analyses and multiple case reports support a beneficial effect of cyclosporine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/20,34,39-42\">",
"     20,34,39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically initiate treatment at a dose of 4 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and subsequently taper as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    therapy can lead to unfavorable side effects, such as renal toxicity and hypertension. Limiting cyclosporine treatment to less than one year is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H17#H17\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178549\">",
"    <span class=\"h1\">",
"     SECOND-LINE AND ADJUNCTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the treatments described above, a variety of other systemic therapies appear to have value for the treatment of PG. Comparative studies of the efficacies of systemic treatments for PG are lacking.",
"   </p>",
"   <p>",
"    Documentation of successful treatment with anti-TNF biologic agents is increasing, and although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    often are not adequate as monotherapy, they may be beneficial when used in conjunction with systemic glucocorticoids or other systemic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3,24\">",
"     3,24",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    also appear to be useful in some patients with PG, and we often attempt to treat patients with mild PG with these generally well-tolerated agents prior to utilizing more aggressive immunosuppressive therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1797000\">",
"    <span class=\"h2\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , a chimeric antibody against tumor necrosis factor (TNF)-alpha, in PG is supported by a placebo-controlled randomized trial of 30 adults with PG, many of whom who were concomitantly treated with topical or systemic therapy (primarily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/43\">",
"     43",
"    </a>",
"    ]. At the start of the trial, patients were given either a single 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infusion of infliximab (n = 13) or placebo (n = 17). After two weeks, significantly more patients in the infliximab group had clinical signs of improvement (46 versus 6 percent).",
"   </p>",
"   <p>",
"    Patients in both groups who did not exhibit improvement at week two were then given open label",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    single dose). At week six, 20 of the 29 patients who received infliximab (69 percent) had improved, and six patients achieved complete remission (21 percent). There was no significant difference in the response to treatment among patients with (n = 18) and without (n =11) inflammatory bowel disease. Long-term follow-up was not performed.",
"   </p>",
"   <p>",
"    In addition to the randomized trial, other studies have documented efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. As an example, a multicenter retrospective study of 13 patients with refractory PG and inflammatory bowel disease treated with 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of infliximab (1 to 24 infusions over zero to four years and in conjunction with other systemic therapies) found that all 13 patients achieved complete healing. The mean times to initial response and complete healing were 11 days (range 2 to 30 days) and 86 days (range 7 to 210 days), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/45\">",
"     45",
"    </a>",
"    ]. Ten patients required periodic infusions every 4 to 12 weeks to maintain the clinical response. All patients who were taking systemic glucocorticoids were able to discontinue glucocorticoid therapy.",
"   </p>",
"   <p>",
"    The treatment regimens for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and the time to response to infliximab vary considerably across case reports and studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/46\">",
"     46",
"    </a>",
"    ]. The optimal treatment regimen is yet to be determined. We typically administer 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of infliximab at weeks zero, two, and six, followed by infusions every six to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/11\">",
"     11",
"    </a>",
"    ]. Given the efficacy of infliximab in Crohn&rsquo;s disease, infliximab may be particularly useful in the population of patients with PG who also suffer from refractory Crohn&rsquo;s disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    include infusion reactions, infections, demyelinating disease, and heart failure. The side effects of TNF-alpha inhibitors are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The requirement for infusion and the high cost of the drug make",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    treatment less favorable for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1710966\">",
"    <span class=\"h2\">",
"     Other biologic TNF-alpha inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , other biologic TNF-alpha inhibitors may be beneficial in PG.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    (40 mg weekly, 40 mg twice monthly, and other regimens) has been associated with ulcer healing in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Most of the published cases have involved patients with concomitant inflammatory bowel disease or rheumatoid arthritis. Improvement in PG with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (25 to 50 mg twice weekly) has also been reported in a small retrospective series and case report [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, in our experience, adalimumab seems to be more efficacious.",
"   </p>",
"   <p>",
"    In theory, other biologic TNF-alpha inhibitors might be useful for PG, particularly in patients with PG-associated diseases that are treated with these agents. The efficacy of drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    (utilized for Crohn&rsquo;s disease) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    (utilized for rheumatoid arthritis) in PG remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178563\">",
"    <span class=\"h2\">",
"     Conventional immunosuppressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    have been utilized for the treatment of PG. The onset of action of these drugs is slower than for systemic glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . These agents are generally considered to be most beneficial when used as adjunctive or glucocorticoid-sparing agents, rather than as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Multiple cases of improvement in PG with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/16,20,40,53-56\">",
"     16,20,40,53-56",
"    </a>",
"    ]. As an example, in a retrospective study of seven patients treated with mycophenolate mofetil for at least two months, four of seven had complete healing, including two patients for whom mycophenolate mofetil was the only systemic therapy given for PG [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/56\">",
"     56",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/57\">",
"     57",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/39,58\">",
"     39,58",
"    </a>",
"    ] as adjuncts to other immunosuppressive therapies is supported by reports of individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical doses utilized for these agents are as follows:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (2 to 3 g per day),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (10 to 30 mg per week), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (100 to 300 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/11\">",
"     11",
"    </a>",
"    ]. Adverse effects of these agents are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1710614\">",
"    <span class=\"h2\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case reports and small series,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    has been associated with improvements in PG when administered as monotherapy or as a glucocorticoid-sparing agent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/20,34,39,40,60-63\">",
"     20,34,39,40,60-63",
"    </a>",
"    ]. Dapsone is usually prescribed in doses of 50 to 200 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, we often attempt treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    prior to more aggressive immunosuppressive therapies in patients with mild disease because of the generally well-tolerated nature of this agent. However, dapsone therapy should be avoided in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to an elevated risk for drug-induced hemolytic anemia in this population. We obtain a G6PD level prior to drug initiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Drugs and chemicals'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\", section on 'Methodology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1710621\">",
"    <span class=\"h2\">",
"     Minocycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    has been linked to improvement in patients with PG when used as monotherapy or a glucocorticoid-sparing agent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/34,64-73\">",
"     34,64-73",
"    </a>",
"    ]. Adult patients can be treated with 100 mg twice daily. Similar to other tetracyclines, minocycline should not be administered to children under the age of nine years due to adverse effects on tooth development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178584\">",
"    <span class=\"h1\">",
"     REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) and the alkylating agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    are options for patients with severe PG that is refractory to first and second-line agents. The high cost of IVIG and the requirement for intravenous infusion limits its routine use. The potential for severe adverse effects limits the use of alkylating agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1179721\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two retrospective studies support the use of IVIG in severe, refractory PG [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. In one study, PG cleared in 7 of 10 patients treated with 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per month divided over three consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/74\">",
"     74",
"    </a>",
"    ]. Reductions in pain and cessation of ulcer progression were detected within one week in most patients. A lower 0.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    dose administered over two to three days was effective in five of seven patients in a separate series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/75\">",
"     75",
"    </a>",
"    ]. In both studies, patients also received systemic glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other immunosuppressive therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2052377\">",
"    <span class=\"h2\">",
"     Alkylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a few case reports and uncontrolled studies document improvement in refractory PG with pulsed intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/76-78\">",
"     76-78",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/79-81\">",
"     79-81",
"    </a>",
"    ], concern for myelosuppression and other severe adverse effects limits the use of these therapies. In an uncontrolled study of nine patients with PG treated with monthly infusions of cyclophosphamide (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for up to six treatments), seven patients achieved complete remission, one achieved partial remission, and one failed to respond to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/76\">",
"     76",
"    </a>",
"    ]. Four patients achieved complete healing prior to the third treatment. Two patients relapsed within three months after the cessation of therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    appeared to be effective for recalcitrant PG in an uncontrolled study of six patients who were treated with chlorambucil (2 to 4 mg per day) with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/79\">",
"     79",
"    </a>",
"    ]. Improvement was noted in six to eight weeks, and healing of ulcers occurred within 2 to 10 months in all patients. All patients who were also receiving prednisone for PG were able to discontinue prednisone therapy. Prolonged remissions (four to nine years) were sustained in four patients who discontinued chlorambucil after 6 to 24 months of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178591\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other interventions have been reported to be effective in individual patients. Examples of topical agents include sodium cromoglycate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/20,82,83\">",
"     20,82,83",
"    </a>",
"    ], nicotine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/84-86\">",
"     84-86",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"     benzoyl peroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/87,88\">",
"     87,88",
"    </a>",
"    ], 5-aminosalicylic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/89\">",
"     89",
"    </a>",
"    ], nitrogen mustard [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/90\">",
"     90",
"    </a>",
"    ], and platelet-derived growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Additional systemic agents that may be beneficial to patients include clofazimine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/39,93\">",
"     39,93",
"    </a>",
"    ], colchicine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], doxycycline [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/34\">",
"     34",
"    </a>",
"    ], interferon alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/96\">",
"     96",
"    </a>",
"    ], melphalan [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/97\">",
"     97",
"    </a>",
"    ], mercaptopurine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/98\">",
"     98",
"    </a>",
"    ], metronidazole [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/99\">",
"     99",
"    </a>",
"    ], potassium iodide [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/100\">",
"     100",
"    </a>",
"    ], sulfasalazine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/40\">",
"     40",
"    </a>",
"    ], tacrolimus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/101\">",
"     101",
"    </a>",
"    ], thalidomide [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/34,102,103\">",
"     34,102,103",
"    </a>",
"    ], and ustekinumab [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Apheresis of leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/106-110\">",
"     106-110",
"    </a>",
"    ] and plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/78\">",
"     78",
"    </a>",
"    ] have also been used for treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14382662\">",
"    <span class=\"h1\">",
"     CESSATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once complete healing of lesions has occurred, treatment cessation can be attempted. Therapy should be gradually tapered and stopped over the course of several months rather than abruptly discontinued.",
"   </p>",
"   <p>",
"    Prolonged treatment is necessary for some patients. In a series of 42 patients with PG who were followed for a median of 26.5 months, 56 percent of the 34 patients who remained alive during the follow-up period required continuing pharmacologic therapy, and 44 percent were able to maintain complete remission without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603344\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcers of PG are often associated with significant pain that appears out of proportion to the clinical appearance of lesions. Although pain may improve during treatment, some patients require the use of narcotic agents to manage discomfort. Consultation with a pain management specialist may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1178633\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up studies of patients with PG suggest that with treatment, more than 50 percent of patients achieve complete wound healing within one year.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an Australian series of 26 patients hospitalized for PG, 6 of 12 patients available for follow-up six months after hospital discharge had complete ulcer healing [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series with 64 patients with classic PG and 22 patients with bullous (atypical) PG, the mean time to complete remission (wound healing and absence of active disease) was 11.5&plusmn;11.1 months in patients with classic PG and 9&plusmn;13.7 months in patients with bullous PG [",
"      <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/1\">",
"       1",
"      </a>",
"      ]. Overall, 68 percent of patients achieved complete remission within six months, and 95 percent were in remission within three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of treatment of associated underlying medical disorders on disease activity in patients with PG is variable, as the course of PG does not always parallel that of the related underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/20\">",
"     20",
"    </a>",
"    ]. Improvement in PG has been reported in some patients following proctocolectomy for inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/112\">",
"     112",
"    </a>",
"    ]. However, PG may also occur peristomally or in other locations following proctocolectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/20,113-117\">",
"     20,113-117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PG typically heals with scars, which can be disfiguring. New lesions may develop during or after healing of other lesions. Relapses can appear after long periods of disease quiescence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Death may occur due to underlying associated disorders, particularly in patients with hematologic disease, or to complications directly related to ulcers (eg, sepsis) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/39\">",
"     39",
"    </a>",
"    ]. Due to the association between bullous PG and hematologic disease, patients with bullous PG who present without an identifiable underlying hematologic disorder should be followed closely [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2054601\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific measures that have been shown to prevent the initial development of PG. In patients with an existing diagnosis, avoidance of trauma may help to reduce the development of new lesions. If patients with pyoderma gangrenosum require surgery for other indications, wound closure with subcuticular stitches and close postoperative follow-up with a dermatologist is suggested.",
"   </p>",
"   <p>",
"    Some authors have suggested that administering systemic glucocorticoids during and for two weeks or more after surgery may help to prevent the development of new lesions in patients with aggressive PG [",
"    <a class=\"abstract\" href=\"UTD.htm?9/61/10202/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the impact of this intervention has not been formally studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=see_link\">",
"       \"Patient information: Pyoderma gangrenosum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2054609\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative disorder that may occur independently or in association with a variety of systemic diseases. (See",
"      <a class=\"local\" href=\"#H1178493\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data on treatments for PG are limited and definitive guidelines for patient management are lacking. Treatment typically involves the use of one or more topical or systemic immunomodulatory agents. (See",
"      <a class=\"local\" href=\"#H1178500\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wound care measures in PG are intended to optimize the environment for wound healing. Wound dressings that maintain a moist wound environment are preferred. Due to the potential for pathergy (exacerbation of PG at sites of tissue injury), unnecessary trauma should be avoided. (See",
"      <a class=\"local\" href=\"#H1178507\">",
"       'Wound management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of surgery is controversial in PG due to the possibility of the induction of pathergy. Surgical procedures should be avoided in most cases. Surgery may be necessary in select cases, such as those in which tissue necrosis presents a risk for infection or in which exposure of vital tissues such as tendons or ligaments is present. (See",
"      <a class=\"local\" href=\"#H1796199\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of PG influences the approach to treatment. For patients with mild, localized PG (few superficial ulcers or a plaque of vegetative PG), we suggest initial treatment with a high potency or superpotent topical corticosteroid or topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with mild PG who fail to improve with local interventions should be treated with systemic therapy. We often attempt treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      prior to the initiation of more aggressive immunomodulatory therapies. (See",
"      <a class=\"local\" href=\"#H1178521\">",
"       'Limited disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with more extensive PG, systemic treatment is indicated. We suggest initiating treatment with systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      , with or without systemic glucocorticoids may be used as an alternative first-line therapy. (See",
"      <a class=\"local\" href=\"#H1178542\">",
"       'More extensive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide variety of other systemic immunomodulatory agents appear to have efficacy in PG.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      was effective for PG in a randomized trial, and may be particularly useful in patients who require treatment of both PG and Crohn&rsquo;s disease. The cost of infliximab and the requirement for infusion are potential limiting factors for the use of infliximab therapy. (See",
"      <a class=\"local\" href=\"#H1178549\">",
"       'Second-line and adjunctive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is estimated that with treatment, more than half of patients with PG achieve wound healing within one year, and almost all patients achieve remission with longer follow-up. However, relapses can occur after long periods of disease remission. (See",
"      <a class=\"local\" href=\"#H1178633\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/1\">",
"      Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000; 79:37.",
"     </a>",
"    </li>",
"    <li>",
"     Powell FC, Hackett BC, Wallach D. Pyoderma gangrenosum. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al.  (Eds), McGraw-Hill Companies, Inc., 2012. Vol 1, p.371.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/3\">",
"      Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/4\">",
"      Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010; 62:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/5\">",
"      Thomas CY Jr, Crouch JA, Guastello J. Hyperbaric oxygen therapy for pyoderma gangrenosum. Arch Dermatol 1974; 110:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/6\">",
"      Davis JC, Landeen JM, Levine RA. Pyoderma gangrenosum: skin grafting after preparation with hyperbaric oxygen. Plast Reconstr Surg 1987; 79:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/7\">",
"      Mazokopakis EE, Kofteridis DP, Pateromihelaki AT, et al. Improvement of ulcerative pyoderma gangrenosum with hyperbaric oxygen therapy. Dermatol Ther 2011; 24:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/8\">",
"      Alam M, Grossman ME, Schneiderman PI, et al. Surgical management of pyoderma gangrenosum: case report and review. Dermatol Surg 2000; 26:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/9\">",
"      Bara��ska-Rybak W, Kakol M, Naesstrom M, et al. A retrospective study of 12 cases of pyoderma gangrenosum: why we should avoid surgical intervention and what therapy to apply. Am Surg 2011; 77:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/10\">",
"      Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005; 53:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/11\">",
"      Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007; 33:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/12\">",
"      Kim DW, Lee BI, Park SH. Accelerated healing of pyoderma gangrenosum in Beh&ccedil;et patient treated with cyclosporine and split thickness skin graft. Ann Plast Surg 2008; 61:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/13\">",
"      Classen DA, Thomson C. Free flap coverage of pyoderma gangrenosum leg ulcers. J Cutan Med Surg 2002; 6:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/14\">",
"      Zakhireh M, Rockwell WB, Fryer RH. Stabilization of pyoderma gangrenosum ulcer with oral cyclosporine prior to skin grafting. Plast Reconstr Surg 2004; 113:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/15\">",
"      Rozen SM, Nahabedian MY, Manson PN. Management strategies for pyoderma gangrenosum: case studies and review of literature. Ann Plast Surg 2001; 47:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/16\">",
"      Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol 2000; 14:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/17\">",
"      Toyozawa S, Yamamoto Y, Nishide T, et al. Case report: a case of pyoderma gangrenosum with intractable leg ulcers treated by allogeneic cultured dermal substitutes. Dermatol Online J 2008; 14:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/18\">",
"      Le Cleach L, Moguelet P, Perrin P, Chosidow O. Is topical monotherapy effective for localized pyoderma gangrenosum? Arch Dermatol 2011; 147:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/19\">",
"      Lyon CC, Stapleton M, Smith AJ, et al. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatolog Treat 2001; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/20\">",
"      Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/21\">",
"      Dohan FC. Schizophrenia and neuroactive peptides from food. Lancet 1979; 1:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/22\">",
"      Jennings JL. Pyoderma gangrenosum: successful treatment with intralesional steroids. J Am Acad Dermatol 1983; 9:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/23\">",
"      Moschella SL. Pyoderma gangrenosum. A patient successfully treated with intralesional injections of steroid. Arch Dermatol 1967; 95:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/24\">",
"      Prajapati V, Man J, Brassard A. Pyoderma gangrenosum: common pitfalls in management and a stepwise, evidence-based, therapeutic approach. J Cutan Med Surg 2009; 13 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/25\">",
"      Larsen CG, Thyssen JP. Pustular penile pyoderma gangrenosum successfully treated with topical tacrolimus ointment. Acta Derm Venereol 2012; 92:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/26\">",
"      Altieri M, Vaziri K, Orkin BA. Topical tacrolimus for parastomal pyoderma gangrenosum: a report of two cases. Ostomy Wound Manage 2010; 56:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/27\">",
"      Marzano AV, Trevisan V, Lazzari R, Crosti C. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatolog Treat 2010; 21:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/28\">",
"      Kimble RM, Tickler AK, Nicholls VS, Cleghorn G. Successful topical tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. J Pediatr Gastroenterol Nutr 2002; 34:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/29\">",
"      Bellini V, Simonetti S, Lisi P. Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2008; 22:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/30\">",
"      Mrowietz U, Christophers E. Clearing of pyoderma gangrenosum by intralesional cyclosporin A. Br J Dermatol 1991; 125:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/31\">",
"      Wenzel J, Gerdsen R, Phillipp-Dormston W, et al. Topical treatment of pyoderma gangraenosum. Dermatology 2002; 205:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/32\">",
"      Theissen U, Luger TA, Schwarz T. [Successful topical administration of cyclosporin A in pyoderma gangraenosum]. Hautarzt 1996; 47:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/33\">",
"      Azizan NZ, Gangaram HB, Hussein SH. A novel therapy for the treatment of pyoderma gangrenosum. Med J Malaysia 2008; 63:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/34\">",
"      Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011; 165:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/35\">",
"      Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Review of 21 cases. Arch Dermatol 1989; 125:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/36\">",
"      Yamauchi T, Ishida K, Iwashima Y, et al. Successful treatment of pyoderma gangrenosum that developed in a patient with myelodysplastic syndrome. J Infect Chemother 2003; 9:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/37\">",
"      Aseni P, Di Sandro S, Mihaylov P, et al. Atypical presentation of pioderma gangrenosum complicating ulcerative colitis: rapid disappearance with methylprednisolone. World J Gastroenterol 2008; 14:5471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/38\">",
"      Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996; 34:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/39\">",
"      von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997; 137:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/40\">",
"      Vidal D, Puig L, Gilaberte M, Alomar A. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J Dermatolog Treat 2004; 15:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/41\">",
"      Hasselmann DO, Bens G, Tilgen W, Reichrath J. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges 2007; 5:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/42\">",
"      Turner RB, Emer JJ, Weill M, et al. Rapid resolution of pyoderma gangrenosum after treatment with intravenous cyclosporine. J Am Acad Dermatol 2010; 63:e72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/43\">",
"      Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/44\">",
"      Mooij JE, van Rappard DC, Mekkes JR. Six patients with pyoderma gangrenosum successfully treated with infliximab. Int J Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/45\">",
"      Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/46\">",
"      Adi��en E, Ozta�� M, G&uuml;rer MA. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy? Dermatology 2008; 216:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/47\">",
"      Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005; 152:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/48\">",
"      Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis 2009; 15:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/49\">",
"      Reddick CL, Singh MN, Chalmers RJ. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab. Dermatol Online J 2010; 16:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/50\">",
"      Cari&ntilde;anos I, Acosta MB, Dom&egrave;nech E. Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:E153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/51\">",
"      Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007; 46:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/52\">",
"      Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol 2006; 54:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/53\">",
"      Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998; 134:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/54\">",
"      Gilmour E, Stewart DG. Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis. Br J Dermatol 2001; 144:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/55\">",
"      Daniels NH, Callen JP. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol 2004; 140:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/56\">",
"      Eaton PA, Callen JP. Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch Dermatol 2009; 145:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/57\">",
"      Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis 1996; 57:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/58\">",
"      Sardar P, Guha P, Das NK, et al. Ulcerative pyoderma gangrenosum in mixed connective tissue disorder: a rare association and role of azathioprine in the management. Indian J Dermatol 2011; 56:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/59\">",
"      Schmidt C, Wittig BM, Moser C, et al. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease. Aliment Pharmacol Ther 2006; 24:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/60\">",
"      Fukuhara K, Urano Y, Kimura S, et al. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 1998; 139:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/61\">",
"      Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea 2007; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/62\">",
"      Brown RE, Lay L, Graham D. Bilateral pyoderma gangrenosum of the hand: treatment with dapsone. J Hand Surg Br 1993; 18:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/63\">",
"      Galun E, Flugelman MY, Rachmilewitz D. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 1986; 81:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/64\">",
"      Farrell AM, Black MM, Bracka A, Bunker CB. Pyoderma gangrenosum of the penis. Br J Dermatol 1998; 138:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/65\">",
"      Shenefelt PD. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis 1996; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/66\">",
"      Boulinguez S, Bernard P, Bedane C, et al. Pyoderma gangrenosum complicating Cogan's syndrome. Clin Exp Dermatol 1998; 23:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/67\">",
"      Langan SM, Powell FC. Vegetative pyoderma gangrenosum: a report of two new cases and a review of the literature. Int J Dermatol 2005; 44:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/68\">",
"      Vandevyvere K, Luyten FP, Verschueren P, et al. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/69\">",
"      Sachs D, Su L, Dlugosz A. Verrucous annular ulcerated hip plaques. Diagnosis: superficial granulomatous pyoderma form of pyoderma gangrenosum. Arch Dermatol 2000; 136:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/70\">",
"      Miralles ES, Nu&ntilde;ez M, P&eacute;rez B, Ledo A. Minocycline hydrochloride hyperpigmentation complicating treatment of pyoderma gangrenosum. J Dermatol 1994; 21:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/71\">",
"      Reynolds NJ, Peachey RD. Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. Acta Derm Venereol 1990; 70:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/72\">",
"      Davies MG, Piper S. Pyoderma gangrenosum: successful treatment with minocycline. Clin Exp Dermatol 1981; 6:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/73\">",
"      Lynch WS, Bergfeld WF. Pyoderma gangrenosum responsive to minocycline hydrochloride. Cutis 1978; 21:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/74\">",
"      Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol 2007; 157:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/75\">",
"      Kreuter A, Reich-Schupke S, St&uuml;cker M, et al. Intravenous immunoglobulin for pyoderma gangrenosum. Br J Dermatol 2008; 158:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/76\">",
"      Reynoso-von Drateln C, Perla-Navarro AV, Gamez-Nava JI, et al. Intravenous cyclophosphamide pulses in pyoderma gangrenosum: an open trial. J Rheumatol 1997; 24:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/77\">",
"      Zonana-Nacach A, Jim&eacute;nez-Balderas FJ, Mart&iacute;nez-Osuna P, Mintz G. Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis: report of 2 cases and review of the literature. J Rheumatol 1994; 21:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/78\">",
"      Kaminska R, Ik&auml;heimo R, Hollmen A. Plasmapheresis and cyclophosphamide as successful treatments for pyoderma gangrenosum. Clin Exp Dermatol 1999; 24:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/79\">",
"      Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol 1996; 35:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/80\">",
"      Callen JP, Case JD, Sager D. Chlorambucil--an effective corticosteroid-sparing therapy for pyoderma gangrenosum. J Am Acad Dermatol 1989; 21:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/81\">",
"      Resnik BI, Rendon M, Kerdel FA. Successful treatment of aggressive pyoderma gangrenosum with pulse steroids and chlorambucil. J Am Acad Dermatol 1992; 27:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/82\">",
"      de Cock KM, Thorne MG. The treatment of pyoderma gangrenosum with sodium cromoglycate. Br J Dermatol 1980; 102:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/83\">",
"      Tamir A, Landau M, Brenner S. Topical treatment with 1% sodium cromoglycate in pyoderma gangrenosum. Dermatology 1996; 192:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/84\">",
"      Patel GK, Rhodes JR, Evans B, Holt PJ. Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream. J Dermatolog Treat 2004; 15:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/85\">",
"      Wolf R. Nicotine for pyoderma gangrenosum. Arch Dermatol 1998; 134:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/86\">",
"      Kanekura T, Kanzaki T. Successful treatment of pyoderma gangrenosum with nicotine chewing gum. J Dermatol 1995; 22:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/87\">",
"      Nguyen LQ, Weiner J. Treatment of pyoderma gangrenosum with benzoyl peroxide. Cutis 1977; 19:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/88\">",
"      Vereecken P, Wautrecht JC, De Dobbeleer G, Heenen M. A case of pyoderma gangrenosum stabilized with lymecycline, topical benzoyl peroxide and treated by autograft. Dermatology 1997; 195:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/89\">",
"      Sanders CJ, Hulsmans RF. Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 1993; 51:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/90\">",
"      Tsele E, Yu RC, Chu AC. Pyoderma gangrenosum--response to topical nitrogen mustard. Clin Exp Dermatol 1992; 17:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/91\">",
"      Braun-Falco M, Stock K, Ring J, Hein R. Topical platelet-derived growth factor accelerates healing of myelodysplastic syndrome-associated pyoderma gangrenosum. Br J Dermatol 2002; 147:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/92\">",
"      Freedman BM, Oplinger EH. Use of becaplermin in progressive limb-threatening pyoderma gangrenosum. Adv Skin Wound Care 2002; 15:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/93\">",
"      Mensing H. Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial. Dermatologica 1988; 177:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/94\">",
"      Paolini O, H&eacute;buterne X, Flory P, et al. Treatment of pyoderma gangrenosum with colchicine. Lancet 1995; 345:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/95\">",
"      Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of Pyoderma gangrenosum with low-dose colchicine. Dermatology 2004; 209:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/96\">",
"      Smith JB, Shenefelt PD, Soto O, Valeriano J. Pyoderma gangrenosum in a patient with cryoglobulinemia and hepatitis C successfully treated with interferon alfa. J Am Acad Dermatol 1996; 34:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/97\">",
"      Jones RR, Kobza Black A, Donaghy M, et al. Defective monocyte function in pyoderma gangrenosum with IgG kappa paraproteinaemia. Clin Exp Immunol 1983; 52:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/98\">",
"      East-Innis A, Desnoes R, Thame K, et al. Pyoderma gangrenosum associated with osteomyelitis in a paediatric patient: a case report. West Indian Med J 2005; 54:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/99\">",
"      Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000; 135:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/100\">",
"      Richardson JB, Callen JP. Pyoderma gangrenosum treated successfully with potassium iodide. J Am Acad Dermatol 1993; 28:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/101\">",
"      Jolles S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999; 140:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/102\">",
"      Kim TH, Oh SY, Myung SC. Pyoderma gangranosum of the penis. J Korean Med Sci 2009; 24:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/103\">",
"      Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 2000; 75:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/104\">",
"      Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011; 147:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/105\">",
"      Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol 2012; 107:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/106\">",
"      Seishima M, Mizutani Y, Shibuya Y, et al. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. Ther Apher Dial 2007; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/107\">",
"      Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol 2004; 151:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/108\">",
"      Kanekura T, Maruyama I, Kanzaki T. Granulocyte and monocyte adsorption apheresis for pyoderma gangrenosum. J Am Acad Dermatol 2002; 47:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/109\">",
"      Okuma K, Mitsuishi K, Hasegawa T, et al. A case report of steroid and immunosuppressant-resistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apher Dial 2007; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/110\">",
"      Watanabe Y, Yamada H. Leukocyte adsorption apheresis for the treatment of pyoderma gangrenosum. J Dermatol 2008; 35:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/111\">",
"      Saracino A, Kelly R, Liew D, Chong A. Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up. Australas J Dermatol 2011; 52:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/112\">",
"      Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985; 55:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/113\">",
"      Abdelrazeq AS, Lund JN, Leveson SH. Pouchitis-associated pyoderma gangrenosum following restorative proctocolectomy for ulcerative colitis. Eur J Gastroenterol Hepatol 2004; 16:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/114\">",
"      Pishori T, Qureshi AH. Post-colectomy peristomal pyoderma gangrenosum. J Coll Physicians Surg Pak 2005; 15:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/115\">",
"      Yanaru-Fujisawa R, Matsumoto T, Nakamura S, et al. Granulocyte apheresis for pouchitis with arthritis and pyoderma gangrenosum after restorative proctocolectomy for ulcerative colitis: a case report. Inflamm Bowel Dis 2005; 11:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/116\">",
"      Holmlund DE, W&auml;hlby L. Pyoderma gangrenosum after colectomy for inflammatory bowel disease. Case report. Acta Chir Scand 1987; 153:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/117\">",
"      Cox NH, Peebles-Brown DA, MacKie RM. Pyoderma gangrenosum occurring 10 years after proctocolectomy for ulcerative colitis. Br J Hosp Med 1986; 36:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/61/10202/abstract/118\">",
"      Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009; 23:1008.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83623 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.147-BCDCD7344F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10202=[""].join("\n");
var outline_f9_61_10202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2054609\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1178493\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1178500\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603390\">",
"      FIRST-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1178507\">",
"      Wound management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1796381\">",
"      - Local care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1796199\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1178521\">",
"      Limited disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1178528\">",
"      - Local corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1178535\">",
"      - Local calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1178542\">",
"      More extensive disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1180235\">",
"      - Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1180242\">",
"      - Systemic cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1178549\">",
"      SECOND-LINE AND ADJUNCTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1797000\">",
"      Infliximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1710966\">",
"      Other biologic TNF-alpha inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1178563\">",
"      Conventional immunosuppressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1710614\">",
"      Dapsone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1710621\">",
"      Minocycline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1178584\">",
"      REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1179721\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2052377\">",
"      Alkylating agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1178591\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14382662\">",
"      CESSATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603344\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1178633\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2054601\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2054609\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/83623\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/83623|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=related_link\">",
"      Patient information: Pyoderma gangrenosum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2328?source=related_link\">",
"      Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_61_10203="Volume regulation";
var content_f9_61_10203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Principle effectors involved in regulation of the effective circulating volume",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic hemodynamics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sympathetic nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiotensin II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal sodium excretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glomerular filtration rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiotensin II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peritubular capillary hemodynamics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aldosterone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sympathetic nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natriuretic peptides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure natriuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma sodium concentration",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10203=[""].join("\n");
var outline_f9_61_10203=null;
var title_f9_61_10204="ACC AHA selection aortic valve";
var content_f9_61_10204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Criteria for selection of an aortic valve in patients undergoing aortic valve replacement (AVR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement for the choice of a mechanical or bioprosthetic valve in",
"patients undergoing AVR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; A mechanical valve in patients who already have a mechanical valve in the mitral or tricuspid position.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; A bioprosthetic valve in patients who will not take or are incapable of taking warfarin or have a major contraindication to warfarin therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or",
"opinion is in favor of the choice of a mechanical or bioprosthetic",
"valve in patients undergoing AVR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; A bioprosthesis in patients &ge;65 years of age who do not have risk factors for thromboembolism.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"1\">",
"        &bull;&nbsp; Patient preference can be considered in patients less than 65 years of age:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. A mechanical valve is reasonable in patients who do not have a contraindication to warfarin therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. A bioprosthetic valve may be chosen after a detailed discussion of the risks of warfarin therapy compared to the likelihood of repeat valve replacement in the future.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; A homograft when aortic valve re-replacement is performed for active prosthetic valve endocarditis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or",
"opinion is less well established for the choice of a mechanical or",
"bioprosthetic valve in patients undergoing AVR in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        &bull;&nbsp; A bioprosthesis in women of child-bearing age to avoid the problems associated anticoagulation during pregnancy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10204=[""].join("\n");
var outline_f9_61_10204=null;
var title_f9_61_10205="Chlorpyrifos structure";
var content_f9_61_10205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chlorpyrifos structure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 162px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10205=[""].join("\n");
var outline_f9_61_10205=null;
var title_f9_61_10206="Framingham ATPIII score men";
var content_f9_61_10206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Framingham/ATP III point scores in men",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age, years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 to 34",
"       </td>",
"       <td>",
"        &nbsp;-9",
"       </td>",
"       <td colspan=\"4\" rowspan=\"10\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35 to 39",
"       </td>",
"       <td>",
"        &nbsp;-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 44",
"       </td>",
"       <td>",
"        &nbsp;0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45 to 49",
"       </td>",
"       <td>",
"        &nbsp;3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 to 54",
"       </td>",
"       <td>",
"        &nbsp;6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55 to 59",
"       </td>",
"       <td>",
"        &nbsp;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60 to 64",
"       </td>",
"       <td>",
"        &nbsp;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65 to 69",
"       </td>",
"       <td>",
"        &nbsp;11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70 to 74",
"       </td>",
"       <td>",
"        &nbsp;12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75 to 79",
"       </td>",
"       <td>",
"        &nbsp;13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Total cholesterol mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 20 to 39",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 40 to 49",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 50 to 59",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 60 to 69",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 70 to 79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;160 (3.4)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160 to 199 (3.4 to 5.15)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 to 239 (5.17 to 6.18)",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        240 to 279 (6.2 to 7.21)",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;280 (7.24)",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 20 to 39",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 40 to 49",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 50 to 59",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 60 to 69",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 70 to 79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsmoker",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoker",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        HDL cholesterol mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;60 (1.55)",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"       <td colspan=\"4\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 to 59 (1.29 to 1.53)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 49 (1.03 to 1.27)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;40 (1.03)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\">",
"        Systolic blood pressure, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Untreated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treated",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td colspan=\"4\" rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        120 to 129",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130 to 139",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        140 to 159",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;160",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Point total",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-year risk, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Point total",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-year risk, percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td colspan=\"2\" rowspan=\"9\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;17",
"       </td>",
"       <td>",
"        &ge;30",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: These risk estimates for the development of coronary heart disease do not account for all important cardiovascular risk factors. Not included are diabetes mellitus (which is considered a CHD equivalent), family history of CHD, alcohol intake, and the serum C-reactive protein concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Adult Treatment Panel III at file://www.nhlbi.nih.gov/ The point total is determined in each category and the 10-year risk determined in the bottom row.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_61_10206=[""].join("\n");
var outline_f9_61_10206=null;
var title_f9_61_10207="Contents: Pediatric rheumatology";
var content_f9_61_10207=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric rheumatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric rheumatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Chronic pain syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/45/7896\">",
"           Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/56/37768\">",
"           Complex regional pain syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20902\">",
"           Growing pains",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/57/19350\">",
"           Treatment and prognosis of fibromyalgia in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dermatomyositis and polymyositis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31079\">",
"           Diagnosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29368\">",
"           Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/5/2138\">",
"           Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33383\">",
"           Approach to evaluating childhood vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14057\">",
"           Evaluation of the child with joint pain or swelling",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint aspiration",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/47/21239\">",
"           Joint aspiration or injection in children: Indications, technique, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/31/28148\">",
"           Joint aspiration: The dry tap",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Juvenile arthritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/56/35717\">",
"           Classification of juvenile arthritis (JRA/JIA)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39994\">",
"           Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41210\">",
"           Pathogenesis of rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/31/24056\">",
"           Pauciarticular onset juvenile idiopathic arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/25/24983\">",
"           Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/48/17162\">",
"           Polyarticular onset juvenile idiopathic arthritis: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12390\">",
"           Psoriatic juvenile idiopathic arthritis: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/40/40584\">",
"           Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/31/8696\">",
"           Spondyloarthropathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21046\">",
"           Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/23/39285\">",
"           Systemic onset juvenile idiopathic arthritis: Course, prognosis, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/9/5274\">",
"           Systemic onset juvenile idiopathic arthritis: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Kawasaki disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/34/11814\">",
"           Incomplete (atypical) Kawasaki disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12248\">",
"           Kawasaki disease: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16183\">",
"           Kawasaki disease: Complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/19/11575\">",
"           Kawasaki disease: Epidemiology and etiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/2/42025\">",
"           Kawasaki disease: Initial treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/52/40775\">",
"           Treatment of refractory Kawasaki disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic myopathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/56/905\">",
"           Approach to the metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21065\">",
"           Causes of metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6134\">",
"           Energy metabolism in muscle",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Office orthopedics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/45/19162\">",
"           Back pain in children and adolescents: Overview of causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/21/16729\">",
"           Overview of hip pain in childhood",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/58/24487\">",
"           Cryopyrin-associated periodic syndromes and related disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/8/15494\">",
"           Periodic fever syndromes and other autoinflammatory diseases: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/14/6376\">",
"           Pathogenesis of sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/63/19450\">",
"           Pathogenesis of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23719\">",
"           Pathogenesis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rheumatic fever",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/20/23879\">",
"           Clinical manifestations and diagnosis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/8/8327\">",
"           Epidemiology and pathogenesis of acute rheumatic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/31/22007\">",
"           Sydenham chorea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44070\">",
"           Treatment and prevention of acute rheumatic fever",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Scleroderma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39433\">",
"           Juvenile systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/1/40985\">",
"           Localized scleroderma in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/63/19450\">",
"           Pathogenesis of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sj&ouml;gren's syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/22/18794\">",
"           Classification and diagnosis of Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11287\">",
"           Clinical manifestations of Sj������gren's syndrome: Exocrine gland disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/42/27306\">",
"           Clinical manifestations of Sj������gren's syndrome: Extraglandular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/36/25162\">",
"           Pathogenesis of Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/11/44212\">",
"           Patient information: Sj������gren���������s syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26826\">",
"           Treatment of dry eyes in Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/57/36762\">",
"           Treatment of dry mouth and other non-ocular sicca symptoms in Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/14/2282\">",
"           Treatment of systemic and extraglandular manifestations of Sj������gren���������s syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Systemic lupus erythematosus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/12/31943\">",
"           Cardiac abnormalities in children and adolescents with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/42/27303\">",
"           Hematologic problems in children and adolescents with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/57/24474\">",
"           Neonatal lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/34/42534\">",
"           Pulmonary manifestations of systemic lupus erythematosus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/35/10810\">",
"           Systemic lupus erythematosus in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vasculitides",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33383\">",
"           Approach to evaluating childhood vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40616\">",
"           Classification and incidence of childhood vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40729\">",
"           Clinical manifestations and diagnosis of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/62/4070\">",
"           Hypersensitivity vasculitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28646\">",
"           Management of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/27/9657\">",
"           Overview of the management of vasculitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/54/5993\">",
"           Renal manifestations of Henoch-Sch������nlein purpura",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-BDC63DD503-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f9_61_10207=[""].join("\n");
var outline_f9_61_10207=null;
           